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CHAPTER I

INTRODUCTION

INTRODUCTION

Ketosis is a metabolic consequence of fasting,
untreated diabetes, disease, or any negative energy balance
in which ketone bodies (beta-hydroxybutyrate and

acetoacetate) are produced by hepatic (and alimentary)
tissues at a rate exceeding extrahepatic utilization
(17,18).

Two classical views for the development of a

ketotic state attribute the accumulation of excessive ketone

bodies to either an excessive hepatic production (18) or a

decreased extrahepatic utilization (17).

Even though

ketosis may develop from decreased peripheral utilization of
ketone bodies, ketogenesis is excessive relative to the
body's ability to utilize the substrates and must result
from a breakdown in intracellular and interorgan
communication that regulates ketone body formation in the
hepatocyte.

Ketone body formation in normal, fed ruminants is

attributed mostly to alimentary ketogenesis, and constitutes
only a minor contribution to energy requirements in most

non-ruminant species.

Volatile fatty acids, particularly

butyrate, that result from microbial fermentation within the

gut lumen, are the predominant source of ketone bodies (59).

Gut epithelial tissues convert butyrate, and some acetate,
to ketone bodies following absorption and subsequent

metabolism (88,133,154).

Butyrate and acetate are activated

to the coenzyme A ester almost immediately following

absorption.

The butyryl-CoA is subject to beta-oxidation,

forming 2 acetyl-CoA moieties.

Depending on the NADH/NAD"*"

of the mitochondria, the acetyl-CoA can either be

metabolized through the tricarboxylic acid cycle, or, if the
ratio is high, condensed to form acetoacetate via 3-hydroxy3-methylglutaryl-CoA pathway (88).

Acetoacetate is then

subject to reduction by mitochondrial beta-hydroxybutyrate
dehydrogenase (85,88), thus helping to relieve the high

NADH/NAD"^ (169).
Alimentary ketogenesis generates 49 /xmol/min of
acetoacetate and 191 jumol/min of beta-hydroxybutyrate in the

normal fed ruminant, which amounts to approximately 7% of
the daily energy requirement for these animals (59).
Considering that the gastrointestinal tract utilizes 20% of

total body oxygen consumption (69,139) and utilizes mostly
volatile fatty acids (134) absorbed from the lumen for

energy, contribution of ketone bodies to meet energy
requirements outside the gastrointestinal tract is probably
closer to 9% for ruminants.

Ketone body concentration in whole blood of fed humans

is 100-150juM and vary in diurnal patterns (165).

In

contrast, ketone body concentration in normal, fed ruminants

is 2-5 times higher due to significant alimentary
ketogenesis, with normal values ranging between 200-500 /xM,
depending on the species (7,8,59,61).

The ratio of

concentrations for beta-hydroxybutyrate to acetoacetate in
fed non-ruminants range from 1.1 to 2.0, whereas the

ruminant exhibits ratios that range from 6 to 25 (17).
of diet affects alimentary ketone body production.

Type

Low

concentrate (high fiber) diets decrease blood beta-

hydroxybutyrate levels relative to high concentrate (low
fiber) diets (64).

This phenomenon is a reflection of

increased butyrate production by the rumen microbes from the
latter diet.

Hepatic fatty acid oxidation is low in fed ruminants,
because rates of fatty acid uptake are low (60).

The liver

extracts 80% of the circulating butyrate but portal
concentrations of this metabolite are extremely low due to
rumen epithelial oxidation and/or conversion to betahydroxybutyrate (10).

Acetate could serve as an additional

source of hepatic ketones, but acetyl-CoA synthetase

activity in sheep liver mitochondria is extremely low (134).
These limitations could account for low hepatic ketone body
production observed in the fed animal (59,74).

Utilization

of ketones by hepatic tissue is not significant, because the

activity of 3-oxoacid-CoA transferase, the enzyme that
activates acetoacetate to the coenzyme A ester, is low in
this tissue (164).

Acetoacetate taken up by ruminant liver

(60) is converted to beta-hydroxybutyrate by betahydroxybutyrate dehydrogenase, which activity is

approximately 95% cytosolic in ruminant liver (85,162).
Beta-hydroxybutyrate is then released back into the blood

for utilization in peripheral tissues (59).
Perturbations of the established normal state, such as
lactation, pregnancy, fasting, and diabetes, can
significantly increase hepatic ketogenesis (59).

This

increase in ketogenesis results mainly from an increase in
blood non-esterified fatty acids and subsequent hepatic

uptake (86,159).

Zonation within the liver for fatty acid

oxidation and ketogenesis has been documented for the rat

liver, although the data is perhaps conflicting.

Early

reports (75) suggested that beta-oxidation was distributed

equally between periportal and perivenous cells as assayed
by 3-hydroxylacyl-CoA dehydrogenase, although ketogenesis

was localized to perivenous hepatocytes.

However, recent

data suggested a periportal localization for both fatty acid

oxidation and ketogenesis as evidenced by higher carnitine
palmitoyl-transferase activity in these cells (57).
Gluconeogenesis in both reports was attributed to periportal
hepatocytes.

Such zonation in ruminants has not been

established, but may exist because of the close relationship
between gluconeogenesis and ketogenesis observed in isolated
bovine hepatocytes (39).

Ketogenesis in the liver operates predominantly by the
hydroxymethylglutaryl-CoA (HMG-CoA) pathway (114).

Alternate pathways of ketone production, i.e. direct
deacylation, can contribute a maximum of 11% of whole body

ketone production in diabetic ketotic rats (125).

This

deacylation contribution was later established to be a
result of high deacylation activity in the kidney and not a
result of a hepatic contribution (26).

Hepatic ketogenesis

in ruminant liver is probably similar to that in rats

because deacylase activity is only one-third the activity of
HMG-CoA synthase in the bovine (9).

Activity of the HMG-CoA

pathway was increased in ketotic cows (107).
condense to form acetoacetyl-CoA.

Two acetyl-CoA

A third acetyl-CoA

condenses with acetoacetyl-CoA to form HMG-CoA, which is
cleaved to yield acetoacetate and acetyl-CoA (114).

The

ketogenic demand of the diabetic liver is so strong, nuclear
magnetic resonance studies have shown that acetoacetyl-CoA
formed in the last turn of beta-oxidation of fatty acids is

used in the HMG-CoA pathway and not subject to being cleaved

to form 2 acetyl-CoA (127).

This in effect would agree with

the limitation of coenzyme-A during ketogenesis that will be
discussed later.

Hepatic production rates of ketones in ruminants have
been reviewed by Heitmann et al. (59).

Fed ruminants

exhibit low hepatic release of ketone bodies, usually less
than 75 /Limol/min.

Lactation and pregnancy dramatically

increased hepatic ketogenesis 3.5-5 fold to rates of 270

and 360 /ixnol/min.

In each of these states, a net hepatic

uptake of acetoacetate was observed.

Fasting and diabetes

have a profound effect on hepatic ketogenesis, with
ketogenic rates of 900-950 /xmol/min.

Hepatic net release of

acetoacetate, instead of a net uptake, was also observed in
fasting and diabetic dogs (78).

Concentration ratios for

beta-hydroxybutyrate to acetoacetate decreased in ketotic
ruminants to around 3, in contrast to high ratios observed
in normal animals (8,14), whereas the ratios increased in
rat, dog, and man during ketosis and fasting (17).

This

difference is probably a reflection of cellular localization
of the beta-hydroxybutyrate dehydrogenase enzyme between

these species.
Utilization of ketone bodies has been directly

correlated to their concentration in the blood (16).

Sites

of utilization are predominantly skeletal muscle, heart, and
kidney.

The lactating mammary gland has been shown to

extract up to 19 and 60% of the acetoacetate and beta-

hydroxybutyrate presented to the organ, in vivo (59,87).
The mammary gland of ketotic cows will extract higher levels
of beta-hydroxybutyrate, but releases acetoacetate (87).
Beta-hydroxybutyrate extracted by the mammary gland can

serve as a minor energy source (89), but mainly contributes
the initial carbons of fatty acids synthesized for release
into milk (128).

The uterus of pregnant ewes preferentially

extracts beta-hydroxybutyrate, which can provide up to 30%

of the organ's energy needs (136).

Ketone bodies have been

shown to provided 12% and 25% of the uterine energy
requirements in pregnant, fed and fasted ewes (135).
Skeletal muscle is a major utilizer of ketone bodies,
preferentially oxidizing ketones over glucose.

Acetoacetate

and non-esterifled fatty acids have been shown to decrease
muscle content of active pyruvate dehydrogenase perhaps by

enzyme inhibition through modulation of free coenzyme A to
acetyl-CoA ratios (2).

Ability to utilize ketone bodies

does seem to vary with the etiology of ketosis in certain

species.

Starvation impaired utilization by 35% in humans,

relative to fed individuals infused with beta-

hydroxybutyrate (11).

Diabetes in rats depressed

acetoacetate utilization to only 50% of that observed in
fasted rats, possibly due to lower free coenzyme A
concentrations associated with the diabetes (143).

However,

no differential effect on utilization was observed in sheep
exhibiting pregnancy toxemia and normal pregnant sheep
infused with acetoacetate (19).

Although ketone body

utilization occurs in skeletal muscle, ketogenic capacity of
this tissue has been observed in diabetes (123).

However,

dual isotope labeling techniques have shown this to be an

artifact (4,49), and attribute this "pseudoketogenesis"

effect to a reversal of 3-oxoacid-CoA transferase activity
(49).

Cardiac muscle, like skeletal muscle, preferentially
oxidizes ketone bodies over other energy substrates, to the

point that beta-oxidation may be decreased through
acetoacetyl-CoA inhibition of acyl-CoA dehydrogenase (104).

Ability to fully oxidize ketone bodies may be impaired due
to fasting.

Activity of 3-oxoacid-CoA transferase in fasted

sheep was 20% of that observed in fed animals (161).

Only a

slight effect on beta-hydroxybutyrate dehydrogenase activity

was observed in sheep (161), although it was decreased by
50% in fasted rat tissues (73).

Beta-hydroxybutyrate may be

extracted preferentially by the heart and converted to
acetoacetate, much of which is released, particularly in
fasting (155,156).
The kidney also may be a ketogenic organ, in vivo (26),
although on a net whole organ basis, the kidney utilizes

ketone bodies in ruminants (76) and probably non-ruminants
(163).

This would suggest a renal zonation of ketogenic and

utilization pathways.

High activities of 3-oxoacid-CoA

transferase (161) and beta-hydroxybutyrate dehydrogenase

(85,161,162) were observed in the renal cortex.

Fasting

decreased renal activity of 3-oxoacid-CoA transferase to 20%
of the fed state, yet no effect on beta-hydroxybutyrate
dehydrogenase was observed in fasted or ketotic sheep
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(161,162).

Net uptake of ketone bodies by the kidney

appears to be concentration dependent, varying from 50
jumol/min in both fed and pregnant ruminants to 75 /xmol/min
in fasting and lactating ruminants (59).
Ketones can serve as an alternate energy source for

nervous tissue.

Short-term fasting in humans has little

effect on ketone body utilization by the brain.

However,

during chronic starvation, ketone bodies become a

significant substrate for utilization (140) due to lack of
available glucose.

Cerebral uptake of ketones has been

shown to be insignificant in short- and long-term fasted
sheep (132).

Activity of 3-oxoacid-CoA transferase in the

cerebral cortex is extremely low in fed sheep, and is almost
completely eliminated by fasting (161).
The role of ketone bodies and regulation of their

synthesis and utilization is complex.

The ability to adapt

to homeorhetic shifts, e.g., lactation in dairy cattle
averaging 18-20 kg/day for 305 days with peak production
greater than 45 kg/day, has yet to be fully elucidated.

It

is of interest that only 3-15% of dairy cattle exhibit

clinical signs of ketosis (6).

Yet more interesting,

treatment of cattle with somatotropin significantly

increases production without concomitant increase in dry
matter intake, yet increased incidence of ketosis has not
been documented.

The regulation of ketogenesis involves

11

hormonal and interorgan substrate signaling which coordinate
production and utilization.

A breakdown in these processes

may well initiate the development of the ketotic state.

CHAPTER II

LITERATURE REVIEW

13

HORMONAL CONTROL OF KETOGENESIS

Hormonal control of substrates and enzyme activities
has been the classical approach for interorgan regulation of

metabolic processes.

Research to fully understand hormonal

regulation has proven to be difficulty and complex.

Only

recently has research attempted to explain hormone-hormone

interactions that play a vital role in the overall metabolic
scheme.

The bihormonal theory of regulation has been suggested
to be the long-term, continuous control of hepatic

ketogenesis (116,117).

It emphasizes the glucagon:insulin

ratio as the determinant of hepatic and peripheral metabolic

function instead of either individual hormone.

Arguments in

support of this theory in the rat model were presented in a

review by these same authors (115).

Ketogenic capacity was

increased by treatment of animals with anti-insulin serum,
establishing an insulin-deficient state, or conversely by
treatment of glucagon alone in an insulin sufficient state.

Concomitant to the increase in ketogenic capacity was a
decrease in liver glycogen (111).

Glucagon:insulin ratio is proposed to regulate hepatic
ketogenesis by two distinctly different mechanisms supported
by work in rats (121), dogs (77), and sheep (33).

In all

species, glucagon (high glucagon:insulin ratio) acted
directly in hepatocytes, enhancing ketogenic capacity, in
vivo.

This has been shown by numerous researchers to

14

involve partitioning of fatty acids within the hepatocyte to
oxidation at the expense of esterification (77,80,117,166).

In contrast, insulin predominantly acts peripherally on

adipocytes by activating cAMP-dependent phosphodiesterase
(102) and regulating non-esterified fatty acids (NEFA)
release from adipose that will be presented to the liver for
oxidation, and possibly ketogenesis.

A direct role for

insulin in regulating hepatic ketogenesis was not observed
independent of glucose (166).

Using livers isolated from

anti-insulin serum treated rats perfused with insulin in
vitro, Woodside and Heimberg (166) observed no effect unless
glucose was added to the perfusion media.

In contrast,

Keller (79) recently implicated a possible effect of insulin

in fasted humans independent of the availability of non-

esterified fatty acid.

Infusion of insulin, resulting in

concentrations slightly higher than that physiologically
normal, with commercial lipid emulsion and somatostatin
resulted in a decrease in blood ketone body concentrations
and peripheral uptake, indicative of a decrease in hepatic
ketogenesis.

Insulin has been suggested to regulate hepatic

acetyl-CoA carboxylase (65,158), which would have an effect

on mitochondrial transport of long-chain fatty acids.
Glucagon acts predominantly at the level of the
hepatocyte in regulating ketogenesis, but concomitant

effects peripherally on muscle or adipose are apparent.
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Independent of insulin, glucagon may act upon peripheral

tissues as observed by an increase in arterial
concentrations of non-esterified fatty acids in diabetic
humans infused with exogenous glucagon (90).

This effect on

peripheral non-esterified fatty acid release has also been
observed in fasted sheep (61).

Glucagon has also been shown

to decrease fatty acid synthesis in adipocytes by cAMP-

dependent protein kinase phosphorylation of acetyl-CoA
carboxylase (66).

This phenomenon may result from binding

of glucagon to other receptors or indirect effect of low
concentrations of insulin in these studies.

Arterial concentration of insulin in ruminants is far

less than that observed in humans, and normally ranges from
20 to 60 juunits/ml (15).

Arterial concentrations decrease

with the onset of lactation in ruminants, possibly due to
diminished response to secretory agents (94).

Responses in

milk production have been observed where concentrations of

propionate, an insulinotrophic agent, were depressed by
diet, thus minimizing insulin production (99).

In addition,

insulin concentrations in fasted sheep were 25% of the fed
animals (61).

Glucagon concentrations do not appear to be

affected by production or starvation (34,61), although
alloxan diabetes may slightly elevate arterial

concentrations (154).

Thus in ruminants the change in the

glucagon:insulin ratios is predominantly due to the
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fluctuation of insulin, although the change in the ratio is

not as pronounced as is the change in insulin (59).

The

lactation discussion here is limited and other factors may
be involved, i.e., synlactin, and possible mammary factors,
to insure successful lactation (1).

Catecholamines provide short-term regulation of hepatic
ketogenesis.

The mechanism of action may be directly on the

hepatocyte by operating via the alpha-adrenergic system in

coordination with calcium-dependent protein kinase (84).
Epinephrine was the more potent stimulator of ketogenesis in
isolated hepatocytes, although simulation appears to be
limited since only a 25 to 30% increase in ketogenesis was
observed (84).

Catecholamines can also increase

ketogenesis, as observed in dogs, by directly simulating
adipose lipolysis and subsequent increase in substrate
supply (153).

Norepinepherine increased circulating

glycerol and non-esterified fatty acids by 50%.

Epinephrine

appeared more efficacious in that it increased glycerol
concentrations by 82%.

Glycerol concentrations remained

high, but non-esterified fatty acid concentrations decreased

with long term catecholamine infusion, suggesting a
stimulation of reesterification in adipocytes (153).

Recent

work has demonstrated a similar effect of epinephrine in

adipocytes isolated from fasted rats (36).

Additional

effects were observed in that epinephrine may be anti-
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ketogenic, in vivo, as evidenced by effect of the hormone on

hepatic ketogenesis.

Several factors may explain this

apparent paradox, such as a decreased non-esterified fatty

acid extraction as well as increased lactate extraction by
the liver.

Somatotropin decreased plasma non-esterified fatty acid
concentrations, without a concomitant increase in

ketogenesis in rats (50).

This would suggest that an

increase in substrate supply without an increase in

glucagon:insulin ratio or catecholamine concentration may

not increase hepatic ketogenesis.

Bovine somatotropin, as a

tool to maintain peak lactation and increase milk output to

energy intake ratios, has been researched extensively with
no significant increases in ketosis reported.

Thyroxine concentrations decreased significantly

following parturition in dairy cattle that later developed
ketosis than in animals that did not exhibit clinical signs
of ketosis (142).

However, no relationship was observed

between thyroxine and the onset of ketosis in these animals

in the ensuing lactation.

In contrast, hyperthyroid humans

had lower glucagon:insulin ratios than normal subjects but

exhibited higher concentrations of glycerol and ketones

(20).

Hyperthyroid rats have decreased beta-hydroxybutyrate

dehydrogenase activities (93), which could decrease the

mitochondrial ability to manipulate redox potential in
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certain tissues by exporting reducing equivalents to the
cytosol as beta-hydroxybutyrate.

This could lead to higher

NADH/NAD"*" levels which in turn may limit available
oxaloacetate for the tricarboxylic acid cycle condensation
with acetyl-CoA and result in increased ketogenesis.

The

ruminant has virtually no mitochondrial beta-hydroxybutyrate

dehydrogenase, thus thyroxine may not effect ketogenesis in
this manner.

INTRAHEPATIC REGULATION OF FATTY ACID OXIDATION AND
KETOGENESIS

Livers of all species discussed are only slightly
ketogenic in the normal, fed state.

Rates of ketogenesis

increase when carbohydrate is directed towards specialized
tissues during homeorhetic responses to pregnancy or
lactation, when not available in sufficient quantities such
as in starvation, or when not effectively transported into
tissues in diabetes (167).

This lack of carbohydrate can

result in low mitochondrial oxaloacetate concentrations as

observed in ketotic rats (86,124,148) and ruminants (5,8),
i.e., Krebs' theory.

High concentrations of glucagon in

these metabolic states have stimulated both gluconeogenesis
and fatty acid oxidation.

Due to the very positive Gibb's

free energy constant for the forward reaction of malate

dehydrogenase, the flux of malate out of the mitochondria

for gluconeogenesis in some species, and the high NADH/NAD"^
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due to beta-oxidation, mitochondrial oxaloacetate

concentrations are low (169).

ketosis than the rat.

Dogs appear less resistant to

An explanation may be the primarily

mitochondrial localization of the gluconeogenic enzyme
phosphoenolpyruvate-carboxykinase in the dog, whereas

cytosolic in the rat, may allow more oxaloacetate to be

directed to tricarboxylic acid cycle use and not to the
gluconeogenic pathway (47).

Likewise, equivalent

localization of the enzyme between both compartments in
ruminants may partially explain their resistance to extreme

ketosis (98).

Although oxaloacetate concentrations may be

depressed in hepatocytes from starved sheep, concentrations
were sufficient to meet tricarboxylic acid cycle
requirements (96).
Contrary to the Krebs' theory, experiments in rats have

shown that the tricarboxylic acid cycle is not affected by
fasting and suggest that partitioning between esterification
and oxidation may be the regulatory mechanism (126).
Malonyl-CoA concentrations are inversely related to

ketogenic rate and addition of this metabolite of fatty acid
synthesis to homogenates and mitochondrial fractions of

fasted rat liver depressed fatty acid oxidation and

increased triglyceride formation (117).

Lack of an

inhibition by malonyl-CoA when octanoate was provided for
oxidation indicated the point of regulation may be at the
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level of the mitochondrial carnitine palmitoyl-transferase
system (116,117).

The flux generating step of fatty acid oxidation is the
initiation of mitochondrial transport on the outer

mitochondrial membrane, i.e., carnitine palmitoyltransferase I (CPTI) (119).

Initial reports of regulation

in isolated enzymes suggested malonyl-CoA to be a
competitive inhibitor (118).

Its role as an allosteric

inhibitor of CPTI was demonstrated in experiments utilizing
membrane fractions instead of the isolated enzyme (120).

Inhibition was almost complete at high physiological

concentrations of 20 /xM malonyl-CoA.

Long chain acyl-CoA

may make malonyl-CoA binding less favorable to the

regulatory site (82).

Regulation of malonyl-CoA concentrations is hormonal,
and possibly substrate mediated, at acetyl-CoA carboxylase.
Glucagon may stimulate fatty acid oxidation and potential
ketogenesis by inhibiting malonyl-CoA synthesis (113,120).
Glucagon, via cAMP-dependent protein kinase, phosphorylates
acetyl-CoA carboxylase resulting in a depolymerization of

the active form (158).

Glucagon also reduces cytosolic

concentrations of citrate (42,120), an allosteric activator

of acetyl-CoA carboxylase.

This decrease in citrate may be

irrelevant because glucagon effects on the enzyme were
reported to be independent of the citrate concentration
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(42).

Insulin counteracts the effects of glucagon by

stimulating activity of acetyl-CoA carboxylase and
increasing citrate concentrations (65).

Phosphorylation of

the acetyl-CoA carboxylase by insulin mediated cAMP-

independent protein kinase at a site other than that

stimulated by glucagon has been suggested to activate the
enzyme (66).

However, recent information has suggested that

phosphorylation is an artifact of isolation, and that

insulin dephosphorylates the enzyme, thus allowing
polymerization, and lowering citrate requirement for
activation (100).

Long chain acyl-CoA has been shown to

suppress malonyl-CoA concentrations (114), possibly by

binding and promoting depolymerization of acetyl-CoA
carboxylase (42).

Malonyl-CoA concentrations can be

increased by glucose, lactate, or pyruvate, in vitro (43).
Fasting increases the effective concentration of

malonyl-CoA needed to inhibit CPTI (29,44).

A possible

mechanism of action has been suggested recently.

Malonyl-

CoA can readily bind to the regulatory site, but does not
effectively transmit to the catalytic site a conformation

change needed to affect activity (82).

Evidence suggests

that this inefficiency may result from an increase in outer

mitochondrial membrane fluidity (83), possibly a direct
result of malonyl-CoA concentrations regulating this
fluidity effect (25).
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Although generally accepted that malonyl-CoA regulates

CPTI activity, the exact binding site is still a matter of
controversy.

The relative mass of CPTI has been shown to be

approximately 90 kDa, whereas the malonyl-CoA insensitive

inner membrane carnitine palmitoyl-transferase II (CPTII) is
a distinctly smaller polypeptide of 66 kDa (108).

The

larger CPTI is believed by some to have the functional

regulatory unit as a part of the polypeptide (110).

Other

work suggests a separate malonyl-CoA binding unit, distinct
from the catalytic unit, which would interact with CPTI.

Isolation of malonyl-CoA binding proteins from CPTI has been

reported following salt elution of CPTI and enzymes of betaoxidation (81).

Similar results were obtained in an

independent laboratory using specific antisera to obtain a

selective precipitation, allowing separate catalytic and
malonyl-CoA binding proteins to be identified (55).

Radiation inactivation analysis in situ suggested separate
catalytic and regulatory components, although a larger
catalytic-regulatory complex was not observed (170).
Other possible regulatory components acting at CPTI

have been identified.

Activation by phosphorylation of the

enzyme by cAMP-dependent protein kinase following glucagon

stimulation in hepatocytes has been documented (58), but has
not been confirmed by additional work.

Malonyl-CoA

regulation explains partitioning of fatty acids between
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esterification and oxidation, but does not account for any
regulation of ketogenesis in ketotic or ketotic-prone
states.

High concentrations of long chain fatty acyl-CoA

competitively inhibit carnitine binding to CPTI, possibly
inhibiting large fluxes of acyl groups into the mitochondria
(30).

In addition, high physiological concentrations of

acetyl-CoA have been shown to inhibit CPTI (109), serving as
a negative feedback mechanism.

Rates of lipogenesis in ruminant livers are extremely
low (13,71).

This observation lead to the speculation that

a pivotal role for malonyl-CoA in these species is unlikely
(6).

However, experimental data provides evidence to the

contrary (31).

Although lipogenic rates are low in

ruminants, malonyl-CoA concentrations are similar to those

observed in rats for fed and starved states of both species.
In addition, sensitivity of isolated hepatic CPTI to
malonyl-CoA is similar for both rats and sheep.
Methylmalonyl-CoA, an intermediate in gluconeogenesis

from propionate, has been implicated in the regulation of

CPTI in sheep liver (32), but not in rat liver homogenates
(117).

Thus, this regulation is considered singular to

ruminants.

Indirect support for a role of this compound in

regulation of CPTI is the observation that propionate added

to bovine liver slices inhibited palmitate oxidation (72).
The physiological advantage to such a role is not well
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understood.

Maximum gluconeogenesis requires at least a

basal rate of fatty acid oxidation and ketogenesis (39).

If

methylmalonyl-CoA depressed rates of fatty acid oxidation
below basal rates by inhibiting CPTI, rates of

gluconeogenesis then could be affected.

A possible role of

methylmalonyl-CoA may be to moderate fatty acid oxidation

and ketogenesis to maintain adequate concentrations of free

CoA for propionyl-CoA synthesis in the mitochondria,
although Bush et al. (35) possibly discounted this effect in
earlier studies.

Regulation by methylmalonyl-CoA is founded on the

premise that the compound can enzymatically be converted to

the mitochondria to a carnitine ester, permeate the

mitochondrial membrane, and become esterified to coenzyme A
in the cytosol (169).

This has not been observed in vitamin

Bi2-deficient rats, where an accumulation of propionyl-CoA
and methylmalonyl-CoA would be expected.

Only propionyl-

carnitine has been identified in isolated hepatocytes and
urinary excretions of these animals by mass spectroscopy
(28).

Low affinity malonyl-CoA binding sites observed to

regulate CPTI have recently been shown to be possible

contaminants of inner mitochondrial membrane OPT (170),

peroxisomal CPT (48), and microsomal carnitine octonoyltransferase (91).

Although speculation, these low affinity
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sites may have evolved in ruminants to prefer methylmalonylCoA, possibly at the level of CPTII.

Two mechanisms of regulation of ketogenesis have been

proposed which rely on intermediates or propionate

metabolism, as reviewed by Zammit (169).

An early report

suggests that propionyl-CoA can inhibit mitochrondrial HMGCoA synthase (35), although an exact mechanism was not

suggested.

An alternative, and possibly related, mechanism

of inhibition is that HMG-CoA synthase auto-succinates

itself in the presence of succinyl-CoA (97).

These

mechanisms are of importance to ruminants in that they
complement the methylmalonyl-CoA mechanism by regulating

ketogenesis from short-chain fatty acids.

Autoregulation of

ketogenesis by acetoacetyl-CoA on HMG-CoA synthase by
substrate inhibition has been proposed because physiological
concentrations of acetoacetyl-CoA are within the
for the enzyme (104,105).

range

Acetoacetyl-CoA has also been

demonstrated to inhibit general acyl-CoA dehydrogenase, the
initial enzyme of beta-oxidation (122).

In either of the

last two cases, effective concentration of acetoacetyl-CoA
may be too low for inhibition in ketotic rats (104),

probably due to mass action effect of the redox potential.

In ruminants, mass action effects of the redox potential in
the mitochondria may not "push" acetoacetyl-CoA to betahydroxybutyrate since acetoacetate is hydrogenated in the
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cytosol (85).

Acetoacetyl-CoA concentrations may then be

higher in these particular animals than that reported for
rats.

During increased fatty acid oxidation, free

mitochondrial coenzyme A concentrations may become depressed
if not for an accumulation of carnitine in the hepatocyte to
relieve this "acetyl pressure" in the mitochondria
(21,24,30,150).

Therefore, concentration of free carnitine

has been postulated to affect rates of ketogenesis.
Intravenous L-carnitine supplementation has been

demonstrated to increase beta-hydroxybutyrate and decrease

non-esterified fatty acid concentrations in humans, thus
implying increased ketogenic rates (3).

Increased non-

esterified fatty acid oxidation and ketogenesis has been
demonstrated in hepatocytes isolated from fasted rats

incubated with L-carnitine (40,41). Similar effects have

been observed with hepatocytes isolated from fed sheep (95).
Fed rats may not have stimulated hepatic non-esterified

fatty acid oxidation and ketogenesis with addition of

carnitine in the perfusate (86) or, in vivo (27), because

high glycogen levels in fed animals may inhibit the effect
(141).

Ruminants have little hepatic glycogen stores (7).

thus may explain the varied results across species in the
fed state.
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Accumulation of carnitine and carnitine esters has been

observed in livers of sheep that were fasted, diabetic, and
pregnant (151).

In contrast, lactation causes a decrease in

hepatic carnitine concentrations in cows (52), although in
ketotic cows, a high carnitine concentrations in plasma and

milk carnitine concentrations was observed (53).

Increases

in free carnitine may also counter the inhibitory effects
that long chain acyl-CoA have on CPTI stated previously.
Additionally, accumulation of carnitine may serve to

regulate the carnitine-acylcarnitine translocase in fasting
and diabetes (129).

This enzyme transfers acylcarnitines

into the mitochondria and free carnitine (or

acetylcarnitine) out of the mitochondria, as reviewed by
Zammit (168).

Bidirectional activity of this enzyme under

ketogenic conditions (129,130) is probably due to mass

action effect of substrates (129). It has been suggested
that carnitine accumulation provides mass action effects
needed for transport of acetoacetate as a carnitine ester

out of the mitochondria during ketogenesis (168).

Such a

role is unlikely since an effective transport of reducing
equivalents, i.e. beta-hydroxybutyrate, would be lost in

some species.

In species that do not use this transport

system, i.e. ruminants, acetoacetate is antiported out of
the mitochondria with pyruvate (169).

Thus, the carnitine

ester of acetoacetate may be rare except, possibly, in
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ketotic animals.

It would seem advantageous to the animal

to effectively regulate carnitine concentrations if
carnitine was able to increase ketogenesis during periods of
high net energy demand.

Such a genetic effect may be

observed in dairy cattle.

Based on this discussion, several factors in regulating
fatty acid oxidation and ketogenesis become apparent.

Beta-

oxidation provides reducing equivalents for glucose
production, as well as acetyl-CoA for further oxidation.

A

role for peroxisomal beta-oxidation was not discussed due to

lack of adequate information, but it could play a role in
diverting fatty acids from the mitochondria.
Gluconeogenesis occurs concomitant to oxidation and

ketogenesis.

Malate, in ruminants, serves to carry reducing

equivalents out of the mitochondria, since beta-

hydroxybutyrate is not formed in this compartment to serve

this function as in other species.

Cytosolic malate is then

subject to gluconeogenesis if NAD'^-malate dehydrogenase is
active at sufficient levels in these species and the

cytosolic redox potential is not high.

Carnitine may be

limiting for fatty acid transport into the mitochondria in

lactating cows, since ketotic cows may have high hepatic
carnitine concentrations (150).

Basal fatty acid oxidation

is needed to provide energy for gluconeogenesis.

Regulation

of fatty acid oxidation and ketogenesis is complex and must

29

be closely coordinated with gluconeogenesis and carbohydrate
metabolism.
AUTOREGULATION OF KETOGENESIS

Increased circulating concentrations of acidic

compounds, such as non-esterified fatty acids, acetate, and
ketone bodies, observed in extreme physiological
perturbations may lower blood pH.

This change in pH may be

of physiological significance, especially in relation to the
action of insulin.

A low physiological pH (approximately

7.0, a level associated with acute diabetes) decreased
insulin binding capacity, in vitro, by accelerating
dissociation of hormone bound to the receptor (103).

The

effect of pH may be insignificant since beta-hydroxybutyrate
has been shown to restore insulin binding to normal in
cultured lymphocytes (106).

In a similar study with

hepatocytes, beta-hydroxybutyrate had a pronounced effect on

restoring insulin binding at pH of 6.9, but very little
effect at normal physiological pH of 7.4 (160).

In the same

study, insulin in the presence of beta-hydroxybutyrate at a
low pH enhanced hexose uptake.

This effect on basal hexose

uptake may be post receptor since the ketone body
potentiated the effects of submaximal insulin concentrations

independent of any effect at the level of receptor binding

in the adipocytes (56).

Circulating non-esterified fatty

acids may counterregulate these actions of ketone bodies
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since they can inhibit insulin action by reducing both the

available hormone binding sites and the rate of receptor
internalization (157).

The combined effects of beta-

hydroxybutyrate and non-esterified fatty acids on insulin

action have yet to be studied.

Insulin stimulated glucose

transport was decreased in adipocytes isolated from animals

supplemented with acetone (a product of spontaneous
acetoacetate breakdown) and its metabolite, acetol (149).
Both beta-hydroxybutyrate and acetoacetate infusions

into partially pancreatized dogs stimulated pancreatic
insulin release (101).

The possible mechanism of the

stimulation for release may be similar to that of glucose
since glucose and ketoacids have been shown to stimulate

insulin release via a common signal pathway in rats (70).
In contrast, beta-hydroxybutyrate did not elicit an increase

in venous insulin concentrations when infused into 1-day
fasted sheep (68), although
suggested otherwise (60).

a subsequent study has

The mechanism for release of

insulin in ruminants may be different because the volatile
fatty acids, propionate and butyrate, are more potent
stimulators of insulin release at equimolar concentrations
to glucose and ketone bodies (68)
Beta-hydroxybutyrate can mediate the non-esterified

fatty acid and glycerol release stimulated by
catecholamines.

In pancreatized, anesthetized dogs, beta-
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hydroxybutyrate inhibited an increase in non-esterified

fatty acids and glycerol concentrations in the blood due to

catecholamine stimulation without insulin supplementation
(23).

Studies, in vitro, using both beta-hydroxybutyrate

and acetoacetate with rat epididymal fat pads suggested that
the mechanism involves an inhibition of the activation of

hormone-sensetive lipase (22).

No effect on deactivation of

the enzyme was observed in this study.

In a separate study,

a correlation of beta-hydroxybutyrate:acetoacetate ratio to

antilipolytic activity suggested that beta-hydroxybutyrate
to be the more potent inhibitor (23).

Balasse and Neef (12)

demonstrated a decrease in ketogenesis with the infusion of
radiolabeled acetoacetate into fasted humans.

These authors

attributed only part of the decreased ketogenic rate to the

antilipolytic effects of ketone bodies, suggesting that
other factors may be involved in hepatic regulation.

Recent

work not only reaffirms an autoregulatory role for ketones

in non-insulin-dependent diabetics, but also shows a
decreased hepatic glucose release independent of insulin and

glucagon, suggesting an intrahepatic regulatory role of
ketones (63)

Research in sheep has suggested a possible hepatic role

in autoregulation of ketogenesis.

Research comparing

hepatic ketogenic rates in diabetic untreated, diabetic
insulin-treated, and normal sheep found that the rates of
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hepatic ketogenesis decreased with the infusion of betahydroxybutyrate (60).

Hepatic extraction coefficients for

non-esterified fatty acids uptake decreased more than the

rates of ketogenesis for the latter two groups, suggesting
that the mechanism may operate at the level of the
hepatocyte.

Further research conducted in alloxan-diabetic

sheep, to eliminate any insulin effect, and infused with
oleate and octanoate emulsions to maintain non-esterified
fatty acids concentrations, observed a decrease in

ketogenesis following beta-hydroxybutyrate infusion only
during the long-chain fatty acid infusion (146).

This

suggested to the authors that an autoregulatory mechanism
may exist at the intrahepatic level of mitochondrial
transport of fatty acyl groups, i.e. carnitine
acyltransferase.
CARNITINE; ROLE AND REGULATION

Work conducted in the 1950's showed a stimulation of

fatty acid oxidation by the addition of carnitine to liver

homogenates.

Since then, the role of carnitine in fatty

acid oxidation for mitochondrial transport of long-chain
fatty acids has been established and well documented (for
review see 21,24,30).
An understanding of carnitine synthesis and

distribution (reviewed in 30,67) is essential for developing
models for carnitine relationships to homeorhesis.

Lysine
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is an essential precursor for carnitine synthesis, being
incorporated into proteins such as myosin and histones (46)
and converted to trimethyllysine with methyl moieties being
donated by s-adenosyl-methionine.

This step is believed to

be catalyzed in the nuclei by (lysine) transferase of
skeletal muscle predominantly, since skeletal muscle has the

largest storage of trimethyllysine (45,46,67), although the
enzyme has been found in all tissues of the rat (30).

Trimethyllysine is released during protein degradation and
is available for carnitine synthesis since it can not be

reincorporated into protein.

Carnitine synthesis may be

dependent on the availability of trimethyllysine (45,138),
although this was not determined to be the case in neonate

rats suckling dams fed lysine deficient diets (46).

an effect was attributed to two possible factors.

Lack of

Lysine

ketoglutarate reductase activity in the dams decreased,

sparing endogenous lysine from degradation, and protein
turnover rates in the neonate are higher (46).

The latter

observation leads to the suggestion that differences in

protein turnover observed in homeorhesis may serve to
regulate carnitine synthesis.

Ketone bodies have been

implicated in sparing protein in starvation (147).
Trimethyllysine, in presence of O2 and alphaketoglutarate, is converted to 3-hydroxy-trimethyllysine by
a mitochondrial hydroxylase enzyme requiring ferrous ions
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and ascorbate.

The enzyme is found throughout most tissues,

but particularly in the skeletal muscle, heart, liver, and

kidney (152).

Serine transhydroxymethylase, a pyrodoxal-5'-

phosphate dependent enzyme (51), then cleaves 3-hydroxyl-

trimethyllysine to form gamma-butyrobetaine aldehyde.

Recent work confirmed the dietary requirement for vitamin Bg
for carnitine synthesis in rats (38).

Distribution of the

enzyme has yet to be determined, but is likely to be found

in all tissues, with concentration highest in the kidney
(62).

Gamma-butyrobetaine aldehyde is then converted to

gamma-butyrobetaine by a specific cytosolic NAD'^-aldehyde
dehydrogenase.

Enzyme activity is highest in the kidney and

liver in humans (30) and, due to the NAD"^ requirement, may
be dependent on the cytosolic redox state.

Carnitine is formed from the hydroxylation of gamma-

butyrobetaine in presence of O2 and alpha-ketoglutarate by a
cytosolic gamma-butyrobetaine hydroxylase, requiring ferrous
ions and ascorbate (92). Product uncoupling of the enzyme
has been suggested, but not studied in detail (30).

Activity is predominantly in the liver of most species,
although the kidneys of rabbits, hamsters, and humans may
have significant enzyme activities.

Enzyme activity has

also been demonstrated in skeletal muscle of adult sheep

(reviewed by 150).

Recent work suggests that a peroxisomal

enzyme similar in function to gamma-butyrobetaine
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hydroxylase, but subject to alternate cellular regulation,
may also exist (131)

Interorgan compartmentalization of carnitine synthesis
has made characterization of its regulatory steps difficult.

Preliminary work based on trimethyllysine supplementation in
rats suggested that the compound is converted in the kidney
to gamma-butyrobetaine (54,62).

Depending on the species,

gamma-butyrobetaine would then be subject to hydroxylation
in either the kidney or the liver.

However, Hoppel and

Davis (67) have proposed that trimethyllysine is converted
to gamma-butyrobetaine in the tissue of protein origin.
Gamma-butyrobetaine then fluxes out of that organ and is
carried to the liver (or kidney) for hydroxylation.

The

compound is extracted and subsequently converted to
carnitine.

In addition, cellular transport of carnitine

into muscle has been suggested to operate by antiport
mechanism with gamma-butyrobetaine, and vice versa, in the
liver (145).

This proposal, in consideration with the

latter observation, provides a possible means of
communication between the muscle and liver as to metabolic

status.

In addition, intrahepatic regulation may also be

involved since the hydroxylation of gamma-butyrobetaine is
not limited in the fed state (137), but was decreased 59% by
fasting (144), thus possibly limiting carnitine synthesis in
the liver and/or kidney.

If ketone bodies are potential
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regulators of protein turnover in diabetes, and possibly
during pregnancy and lactation, then the muscle could

communicate with the liver that utilization is impaired by
decreasing available carnitine precursor.

Just as fatty

acid and carbohydrate metabolism are closely coordinated, so
may be fatty acid metabolism, protein turnover, and
carnitine synthesis.
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CHAPTER III

EFFECTS OF BETA-HYDROXYBUTYRATE AND CARNITINE

ON HEPATIC FATTY ACID METABOLISM AND KETOGENESIS
IN ALLOXAN-DIABETIC EWES METABOLIZING OCTANOATE
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ABSTRACT

To study an insulin-independent autoregulatory

mechanism of hepatic ketogenesis, catheters were placed

in

hepatic (H), portal (P), mesenteric (M), and femoral (V)
veins, and femoral artery (A) of 5 ewes made diabetic with
alloxan (.05g/kg bw, iv).

Euglycemia was maintained with

daily insulin injections until 3 d prior to experiment, when
injections were withheld to induce ketosis.

Experiments

consisted of 4 infusion periods: (1) p-amminohippurate (PAH,
1.5% § .764 ml/min) infusion into M (Control); (2) PAH as in

(1) and octanoate (08, 3.2 mmol carbon/min) into M; (3) PAH

and 08 as in (2) and B-hydroxybutyrate (BOHB, .4 mg/kg^/^)

into V; and (4) PAH, 08 and BOHB as in (3) and carnitine (0,
1.18 mM/min) into V.

For each period, 3 blood samples were

taken simultaneously from H, P, and A at 15 minute intervals

and analyzed for ketones, non-esterified fatty acids (NEFA),
glucose and PAH.

Relative to control, 08 decreased P and H

blood flows (3.1 and 3.7 vs. 1.9 and 2.4 1/min, P<.05) and

increased net hepatic NEFA uptake (416 vs 629 jumol/min,
P<.05). Relative to 08, BOHB decreased hepatic NEFA uptake
(629 vs 424 /xmol/min, P<.05) and increased plasma free

carnitine (13.0 vs 15.5 /nM, P<.l). Relative to BOHB,
carnitine increased hepatic glucagon uptake (1.95 vs 4.08
Mg/hr, P<.1) and extraction percent (4 vs 11 %, P<.05).
Hepatic ketogenesis did not change with treatments.

This

57

data suggests that BOHB does not have an inhibitory effect

on hepatic ketogenesis and that carnitine is not limiting
for hepatic fatty acid oxidation when C8 is the primary
fatty acid metabolized.
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INTRODUCTION

The bihormonal theory explains the regulation of fatty
acid oxidation and ketogenesis in the normal, fed animal and
the shift to a high ketogenic state in fasted, diabetic, and
lactating mammals (34).

Regulation of hepatic ketogenesis

within these homeorhetic states is not as well understood,
but is believed to be result primarily from ketone body
autoregulatory mechanisms.
Ketone bodies have been show to stimulate pancreatic

release of insulin (31).

This mechanism has been suggested

not to exist extensively in ruminants (24), although work by
Heitmann and Fernandez (21) suggested otherwise.

Although

ketogenic rates during lactation in ruminants are high
relative to the normal animal (2) and insulin concentrations
appear to be decreased during lactation (30), incidence of

ketosis in dairy cattle is not greater than 15% (data
compiled by 2).

Ketone bodies have been shown to decrease

plasma NEFA concentrations (10), possibly by decreasing

lipolysis by inhibiting activation of adipose hormonesensitive lipase (9).

The reduced availability of substrate

could decrease hepatic ketogenesis (for review 34).

This

may be important to ruminants since infusion of ketone
bodies has been shown to decrease arterial concentration of

NEFA in sheep (21).
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Balasse and Neef (3) observed concomitant decrease in

circulating ketones with infusion of ^^C-acetoacetate in
fasting humans that could not be fully explained by the
decrease in circulating NEFA concentrations.

Similar

effects have been observed also in rats (6).

Infusion of

beta-hydroxybutyrate has been shown to decrease hepatic NEFA

extraction ratios in both fed, normal and insulin-treated,

diabetic sheep (21).

The infusion of beta-hydroxybutyrate

had no affect on hepatic insulin uptake in the insulin-

treated, diabetic animals, suggesting a possible insulin-

independent autoregulation of ketogenesis.

A subsequent

study in diabetic sheep has shown that infusion of betahydroxybutyrate decreased hepatic ketogenesis from oleate
infused animals, but had no affect on animals infused with

octanoate (39).

The dependence of long-chain, but not

medium-chain, fatty acids metabolism on carnitine for

mitochondrial transport has been established (for review
8,13,34).

Infusion of ketone bodies has been shown to

decrease hepatic glucose output in non-insulin-dependent
diabetics prior to the decrease in plasma NEFA concentration
(23).

Dependence of gluconeogenesis on ketogenesis has been

established in isolated ovine hepatocytes (15).
Fasting in rats has been associated with an increase in
short chain acylcarnitines that correlated with the increase

in ketone body concentration (12).

In nonruminants, short
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chain acylcarnitine is believed to be exclusively
acetylcarnitine, whereas in ruminants, acetylcarnitine was
only 88% of the hepatic short chain acylcarnitines of 7fasted animals (41).

Therefore, the purpose of this study was to establish

if beta-hydroxybutyrate decreases hepatic ketogenesis from
octanoate independent of insulin and the subsequent effects
that carnitine may have on hepatic metabolism.
MATERIALS AND METHODS

Five non-pregnant, non-lactating, alloxan-diabetic ewes

weighing 55 to 65 kg were housed individually in 1.8 X 3.0 m
indoor pens with ambient temperature maintained between 19

and 25°C and under natural lighting.

Commercially prepared

alfalfa pellets were fed in two daily aliquots of 400 g at
0800 and 1700 h.

Water and trace mineralized salt were

provided ad libitum.

Animals were accustomed to laboratory

personnel prior to any experimentation and no restraint was
required for sample collection.

Catheters were surgically positioned into mesenteric,

hepatic, portal and femoral veins, and femoral artery of
each animal (see appendix 1 for diagrams), as described by
Katz and Bergman (27) and modified by Zanzalari et al. (47).

Due to concerns over catheter patency, the mesenteric artery
that ran parallel to catheterized mesenteric vein was also

catheterized as an alternate artery sampling site.

Ten days
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following surgery, each animal was made pharmacologically

diabetic with a single intravenous dose of alloxan (Sigma
Chemical Co.) at 50 mg/kg body weight (21) between 1300 and
1700 h.

On the following day, glucose was monitored to

determine if diabetic state was established.

Animals

determined to be diabetic then received daily subcutaneous
doses of insulin (Iletin NPH-100, "40 U/d) at 1700 h to

reestablish and maintain euglycemic conditions (2.5 to 3.5

mM).

Insulin was withheld 3 d prior to the experimental

date to establish a ketotic state and allow for the study of
insulin-independent effects.

On the experimental day, animals were subjected to

consecutive infusates superimposed over four time periods

(see Figure 3.1). Each period was two hours in length,
allowing one hour for equilibration of each additional

infusate and one hour for collecting samples.

The

equivalence of a 30 minute infusion for each new infusate
was pulsed into the infusion site at the initiation of each

period.

The control period began at 0800 h with para-

aminohippurate (PAH, 1.5% w/v, Eastman-Kodak Co.) being
infused into mesenteric vein at 0.764 ml/min (Model ,
Harvard Apparatus).

Following sampling, the octanoate

period began with octanoate (233 mM solution, Sigma Chemical
Co.) infused constantly into the mesenteric vein at a rate

of 3.2 mM carbon/min.

The beta-hydroxybutyrate period
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Time

(min)

-Infusates-

PAH

0
60
90

1
1
1

125
180

1
1

240

1

300
330
360

1
1
1

420

1

480

1

120

210
245

365

450

1

1

1

C8

Cam

Comment

Start PAH infusion

Sample lA, IH, IP
Sample 2A, 2H# 2P
Sample 3A, 3H, 3P

1
1

Start Octanoate infusion

Sample 4A, 4H, 4P
Sample 5A/ 5H, 5P
Sample 6A, 6H, 6P

1
1

1

1
1
1

1

1

1

1

FIGURE 3.1.

BOHB

1

1

1
1
1
1

1
1
1
1

1
1
1
1

Start BOHB
Sample 7A,
Sample 8A,
Sample 9A,

infusion
7H, 7P
8H, 8P
9H, 9P

Start Carnitine infusion
Sample lOA, lOH, lOP
Sample llA, llH, IIP
Sample 12A, 12H, 12P

OUTLINE OF INFUSION PERIODS FOR OCTANOATE STUDY
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followed with infusion into the femoral vein at 1.18 mM/min
of dl-beta-hydroxybutyrate (1.6 M solution, Sigma Chemical
Co.) which corresponds to a rate similar to maximum

utilization in diabetic sheep (7).

Finally, the carnitine

period consisted of 1-carnitine (Sigma Chemical Co.) being
infused into the femoral vein at a rate eguimolar to the

beta-hydroxybutyrate infusion.

Sampling within each period

consisted of three blood samples taken at 30 min intervals

simultaneously from the hepatic (11 ml) and portal (11 ml)
veins and femoral artery (15 ml).

Each sample was

immediately immersed in an ice water bath and assayed as
described below (see Appendices for each assay protocol,

listing appears on contents page).

Between experimental

days and throughout all experimental periods, catheter
patency was maintained with 6% NaEDTA solution.

After all

sampling was completed, plasma was separated and immediately
frozen in individual aliquots for future analysis of
glucagon, carnitine, and insulin.

All other analysis were

performed on the day of the experiment.
Acetoacetate, beta-hydroxybutyrate, and PAH values for

whole blood and NEFA, glucagon, and free and acid soluble
acylcarnitines values for plasma were determined for all

samples.

Hematocrits, blood glucose, and plasma insulin

values were monitored only on femoral artery samples.
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Plasma percent was determined by subtraction of the
hematocrit value from 1.

A one milliliter aliquot of whole blood was analyzed
for PAH as described by Kaufman and Bergman (28).

An

additional 2 ml of whole blood was deproteinated in an equal
volume of cold 1 M perchloric acid as discussed previously
(21) and analyzed for acetoacetate and beta-hydroxybutyrate
by the spectrophotometric, enzymatic method of Williamson

and Mellanby (45).

Glucose was determined by analyzing 200

jul of whole blood with a commercial spectrophotometric

enzymatic kit (Sigma Chemical Co.) -

Non-esterified fatty

acids were determined by analyzing freshly isolated plasma
with the commercially available NEFA-C kit (Wako Chemical
Co.).

Insulin and glucagon were measured by a standard double
antibody radioimmunoassay technique (48).

The first insulin

antibody was guinea pig anti-bovine insulin (Research
Products International) and the second was anti-guinea pig

GIG (Miles Laboratories Inc.).

The first glucagon antibody

was rabbit anti-glucagon antibody (R. H. Unger, University
of Texas Health Sciences Center, Dallas) and the second was

anti-rabbit GIG (Research Products International).

Free and

acid-soluble acylcarnitine concentrations were determined

radioenzymatically (14) as modified by Sachan et al. (38)

using ^"^C-acetyl coenzyme A (NEN-Dupont) .
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Blood flow rates were determined by dividing the rate
of PAH infusion (optical density units/min) by the

venoarterial PAH concentration differences (optical density
units/L) across each specific tissue.

Blood flow rates for

hepatic and portal veins were measured directly and the
hepatic arterial flow represented the difference between the
two known values.

Plasma flow rates were determined by

multiplying blood flow rates by plasma percent .
The equations for net flux calculations have been

published previously (22, also presented in Appendix 2) and
are simply the venoarterial concentration differences across

the tissue multiplied by the respective blood flow rate.

Positive values are indicative of a net release, whereas

negative values indicate a net uptake, of the metabolite by
that tissue.

These values do not represent unidirectional

flux, and should not be interpreted as such.

Hepatic

extraction ratios were calculated as the fraction of the

metabolite taken up by the organ relative to the total
concentration presented to the organ per unit time.
Significant differences between treatments would indicate

intraorgan effect independent of blood flow and
concentrations.

Statistical analysis involved comparing subsequent
means of consecutive treatments without inference to any
other treatments.

Means were separated by an unpaired t-
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test within and among sheep and significance was considered
at the levels of P < 0,1, P < 0.05, and P < 0.01.
RESULTS

Portal and hepatic whole blood flow rates, portal to
hepatic ratios, and plasma percent values for each treatment

are summarized in Table 3.1.

Portal and hepatic blood flow

rates were 3.1 and 3.7 L/min during the control period and

are higher than those observed previously in diabetic,
untreated animals (21).

Octanoate infusion decreased blood

flow rates by 40% (P<.01).

No subsequent effect on whole

blood flow rates was observed due to beta-hydroxybutyrate or
carnitine infusion.

Portal to hepatic ratio was

approximately 80% and not affected significantly by any
i^r®3tment.

Infusion of octanoate increased plasma percent

(P<.1) which, in combination with the effects on whole blood

flow rates, resulted in decreased hepatic and portal plasma
flow rates of 35% (P<.01). Effects of octanoate on plasma
levels may have been a time effect due to blood sampling,
but can not be delineated from treatment due to nature of

experimental design.

The effect of octanoate on whole blood

flow rates cannot be physiologically explained.
Arterial NEFA concentrations appear in Table 3.2 and

hepatic venoarterial differences appear in Appendix 3 (Table
A3.1) for each treatment.

Control arterial NEFA

concentrations of were 2028 /xM, very similar to values

TABLE 3.1

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusions on blood

flow rates, portal hepatic flow ratios, and plasma percent in untreated, alloxan-diabetic
ewes.

•

Treatment

Hepatic

Portal
Vein
Blood
Flow

Vein
Blood
Flow

Portal/
Hepatic

Plasma

Ratio

Percent

(1/min)—
Control

3.1

-(%)-3.7
± .24

.84

72

+

.02

± 2

.29

+

.04

2.4
± .26

.80

78

+

.04

± 1

.81

78

+

.04

± 1

+

.23

+

.26

+

2.0
+

.26

+

.31

1.9***

Octanoate

BOHB

Carnitine

2.4***

1.9

.77

2.3
+

.31

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

76*
± 1

Significantly different from the preceding infusion period, P < .05,
•kick

Significantly different from the preceding infusion period, P < .01,

cr>

TABLE 3.2

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on blood

plasma NEFA arterial concentrations and corrected net flux rates in untreated, alloxan-

diabetic ewes.^*

Treatment

Arterial

Portal
Drained
Visceral

Octanoate

Carnitine

Ratio

(%)

Total

Splanchnic
(|imol/min)

2028

-154

-416

.09

-570

± 140

± 62

± 53

± 1

± 86

-70

-629

.22

-699

± 17

± 67

± 2

± 63

1056***

,,„***
-149

-424

.21

-573

± 93

± 15

± 34

± 2

± 28

942

-124

-366

.20

-490**

± 19

± 34

± 2

± 24

1603*
± 162

BOHB

Extraction

Hepatic

(/imol/min)

--(/iM) —
Control

Hepatic

± 73

***

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

_ _^

Significantly different from the preceding infusion period, P < .05.
***

Significantly different from the preceding infusion period, P < .01.

a\
00
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reported previously for diabetic, untreated sheep (21).

Octanoate infusion decreased arterial concentrations by 20%
(P<.1).

Subsequent infusion of beta-hydroxybutyrate

resulted in an additional 35% decrease in arterial

concentration of NEFA (P<.01).

Considering venoarterial

differences, octanoate increased hepatic vein-portal vein
differences (P<.01), but had no effect on hepatic vein-

hepatic artery NEFA differences.

An increase in portal

vein-hepatic artery differences was observed with octanoate
infusion, but this was because the site of infusion was the

mesenteric vein, which is directly upstream to the portal
vein.

The beta-hydroxybutyrate infusion decreased NEFA

differences for both the hepatic vein-portal vein (P<.01)
and the hepatic vein-hepatic artery (P<.05).

Infusion of

carnitine decreased the hepatic vein-hepatic artery (P<.05),
but had no effect on hepatic vein-portal vein differences
(P>.1).

Net rates of NEFA flux corrected for octanoate infusion

and hepatic extraction ratios appear in Table 3.2.

Net

hepatic NEFA uptake for the control period was approximately
416 jumol, similar to that reported previously for diabetic,
untreated sheep (21).

Hepatic extraction was nearly 10%,

slightly lower than the 16% previously reported for
diabetic, untreated sheep (21).

Infusion of octanoate

dramatically increased hepatic uptake of NEFA by 50% (P<.05)
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and hepatic extraction by nearly two-fold (P<.01).

In

contrast, subsequent infusion of beta-hydroxybutyrate
decreased hepatic uptake (P<.05), but had no effect on

hepatic extraction ratios.

Values originally calculated for

portal drained visceral and total splanchnic fluxes (see
Appendix 3 Table A3.2) are artifactual due to the octanoate
infusion into the mesenteric vein.

Octanoate was infused

constantly at a rate of 3.2 mmol carbon/minute, which
corresponds to 400 /imol of fatty acid since octonoate is an
8 carbon fatty acid.

Correction for this infusion on these

fluxes resulted in values quite similar to control values,

though some differences do exist.

In contrast to hepatic

flux, octanoate infusion decreased, although not

significantly, net portal drained visceral uptake of NEFA
(P>.1).

These opposing effects of octanoate infusion

resulted in a total splanchnic flux that was not

significantly different from control, therefore peripheral
release must be decreased.

Conversely, infusion of beta-

hydroxybutyrate increased portal drained visceral uptake
(P<.01) back to control values.

This increase in uptake was

not large enough to offset the decreased hepatic uptake,

resulting in a net decrease in total splanchnic uptake
(P<.1) to control values.

Subsequent infusion of carnitine

had no significant effects on NEFA fluxes for portal drained
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viseceral and hepatic tissues, but decreased total
splanchnic uptake by 20%.
Whole blood arterial concentrations and net fluxes for

acetoacetate and beta-hydroxybutyrate in Tables 3.3 and 3.4

(venoarterial differences are presented in Appendix 3 Tables
A3.3 and A3.4).

The control concentrations for acetoacetate

and beta-hydroxybutyrate were 762 and 7441 /xM.

Octanoate

did increase significantly arterial concentration of
acetoacetate (P<.01), but not beta-hydroxybutyrate.

Infusion of beta-hydroxybutyrate increased the
concentrations of beta-hydroxybutyrate and acetoacetate 1.9

(P<.01) and 1.1 ((P<.05) fold, as well as the beta-

hydroxybutyrate to acetoacetate ratio from 9.4 to 14.1
(P<.01).

Subsequent infusion of carnitine tended to

increase the concentration of beta-hydroxybutyrate only
slightly (P<.1).
Octanoate did not affect acetoacetate net flux rates,

but it decreased net portal drained visceral beta-

hydroxybutyrate release (P<.05).

Subsequent infusion of

beta-hydroxybutyrate decreased net acetoacetate uptake from

portal drained visceral, and net release from the hepatic
and total splanchnic tissue beds (P<.01).

In contrast, no

effect of this infusate was observed on net beta-

hydroxybutyrate flux of any tissue measured.

Subsequent

TABLE 3.3

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on
acetoacetate arterial concentrations and net flux rates in untreated, alloxan-diabetic
ewes.^•

Portal

Treatment

Arterial

Drained
Visceral

Octanoate

BOHB

Carnitine

206

190

± 30

± 29

± 46

910

-47

168

121

± 32

± 7

± 32

± 30

1016**

-11***

± 20

± 9

± 10

± 10

1029

-6

44

39

± 33

± 21

± 8

± 17

762

-16

± 27

36***

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05,

***

Splanchnic

(/imol/min)

--(MM)-Control

Total

Hepatic

***

25

Significantly different from the preceding infusion period, P < .01.
N>

TABLE 3.4

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on beta-

hydroxybutyrate arterial concentrations and net flux rates in untreated, alloxan-diabetic
1.

ewes.

Treatment

Arterial

Portal
Drained
Visceral

Octanoate

7441

431

1240

1671

± 485

± 152

± 170

± 154

8416

-69

1475

1406

± 612

± 114

± 146

± 119

"k "k "k

BOHB

Carnitine

Splanchnic

(Mmol/min)

--(MM) —
Control

Total

Hepatic

14187

223

1584

1807

± 675

± 208

± 281

± 287

16418*
± 1027

117

2022

2139

± 281

± 684

± 764

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05,

***

Significantly different from the preceding infusion period, P < .01.

•v)
U)
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infusion of carnitine appeared had no affect on rates of
either ketone body flux.
Arterial concentrations, net flux rates, and hepatic
extraction ratios for plasma glucagon are presented in Table
3.5.

None of the infusates significantly affected arterial

glucagon concentrations nor net flux rates significantly
(P>.05).

Infusion of carnitine did tend to increase the net

hepatic uptake (P<.1) and increased the extracion ratio
nearly 3 fold, but had no effect upon portal-drained

visceral release of glucagon.

The effect on glucagon flux

by carnitine infusion appeared to be a result of increase

hepatic vein-portal vein extraction (P<.05, see Appendix 3
Table A3.5) and with no effect on hepatic vein-hepatic
artery differences.
Plasma arterial concentrations for free and acid-

soluble acylcarnitines appear in Table 3.6.

Net flux rates

for free and acid-soluble acylcarnitines for each tissue
were calculated and reported in Appendix 3 (Tables A3.6 and
A3.8).

These fluxes were small and could not be shown to

significantly different from zero.

Values of acid-soluble

acylcarnitine represent short- and medium-chain

acylcarnitines. Carnitine concentrations during the control
period were 13.7 /xM for free and 40.7 /xM for acid-soluble
acylcarnitine.

Values for free carnitine are similar to

those reported previously in blood for lactating ruminants

TABLE 3.5

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on

glucagon arterial concentrations and net flux rates in untreated, alloxan-diabetic ewes. '

Treatment

Arterial

Portal

Hepatic

Drained
Visceral

Extraction
Ratio

Hepatic

Octanoate

263

Carnitine

6.30

-4.50

8

1.80
± 1.61

± 33

± 1.14

± 1.23

± 1

284

5.33

-2.24

6

3.09

± 1

± 1 16

± 18
BOHB

Splanchnic

(/xg/hr)

-(pg/ml)Control

Total

± 1.11

± .46

279

6.51

-1.95

4

4.56

± 11

± .81

± .60

± 1

± 1.17

283

6.44

-4.08

11

± 17

± .93

± .80

± 2

- - **

1.

Means ± standard error of means, n = 12, 3 measurements on 4 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.

2.36
± 93

TABLE 3.6

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on
arterial concentrations of free carnitine, acid-soluble acylcarnitine, glucose, and

insulin in untreated, alloxan-diabetic ewes.^*

Acid-soluble
Treatment

Free

Acyl

Carnitine

carnitine

Glucose

(^M)
Control

Octanoate

13.7

40.6

9.4

± 2.8

± .3

13.0

38.4

9 4

± .9

± 3.0

± .3

34.4

9.5

± 2.2

± .3

1152.0

10.2

± 86.0

± .4

± 1.0

Carnitine

5082.0***
± 296.0

Means

(/xU/ml)

± .6

15.5*

BOHB

Insulin

± standard error of means. n = 15, 3 measurements on 5 ewes.

*

Significantly different from

the

preceding infusion period, P < .1.

**

Significantly different from

the

preceding infusion period, P < .05.

*** Significantly different from

the

preceding infusion period, P < .01.

7.8

± .3
8.6
± .4
_

_ **

9.9

± .3
.-

_ **

11.0

± .3

77

with concentrations approximately 9 /liM (20).

Octanoate

infusion did not affect carnitine concentrations.

In

contrast, beta-hydroxybutyrate infusion tended to increase
free carnitine concentration to nearly 15.5 /xM (P<.1)
without a concomitant significant decrease in acid-soluble
acylcarnitine.

Subsequent infusion of carnitine elevated

both free and acid-soluble carnitine concentrations (P<.oi).
This effect would imply the uptake of free carnitine and
subsequent acylation by some tissue not measured.

Arterial blood glucose concentrations and plasma

insulin concentrations also are presented in Table 3.6.
Diabetic, untreated ewes had 3 fold higher glucose
concentrations than reported for normal sheep (21,22)
indicative of a diabetic state.

Insulin arterial

concentrations are low and significantly different from
zero.

These values are less than those reported for normal

animals (5), and may represent some cross reactivity of the
assay with other plasma proteins observed previously (21).
It would thus appear that insulin interaction in this study
may have been limited but perhaps not totally eliminated.
Increases in arterial insulin concentrations presented
following octanoate infusion are believed not to be due a

physiological event.

Hemolysis was observed in the plasma

samples collected from this point on and could have cross-

reacted and interfered with the insulin assay.
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DISCUSSION

Previous work has demonstrated that beta-

hydroxybutyrate can lower circulating NEFA concentrations
and subsequent ketogenesis in the dog (10) and rat (9).
Balasse and Neef (3) were able to demonstrate a similar
effect in fasted humans with acetoacetate infusion, without
changes in peripheral insulin concentrations.

In addition,

these researchers suggested that the antilipolytic effect of
ketone bodies did not solely explain the antiketogenic
effect observed.

Recent work in 1-d fasted and diabetic

sheep (21) has verified antipolytic effect of betahydroxybutyrate for this species and, in addition, has

implicated an hepatic mechanism of autoregulation.
Subsequent work in diabetic sheep was able to differentiate

regulation of ketogenesis between exogenous octanoate and
oleate, with no observed antiketogenic effect of betahydroxybutyrate when octanoate was infused (39).

It is

established that octanoate and oleate are metabolized

similarly, except that carnitine mediated transport into the

mitochondria is required for long chain fatty acid
metabolism (33).

Blood carnitine concentrations are

increased three fold in ketotic dairy cows (20).

The

objective of the present study was to reaffirm the lack of

an hepatic mechanism for autoregulating ketogenesis with
octanoate and to study the role of carnitine and hepatic

metabolism under these experimental conditions in ruminants.

79

Hepatic and portal whole blood flow rates during the
control period in these animals were higher than those

reported previously (21).

Infusion of octanoate decreased

blood flow rate to 60% of control rates and maintained this

suppression throughout the subsequent infusion periods.
This effect appeared to be due to octanoate infusion as no

other parameter change could be solely associated with the
decrease in blood flow rates.

Paradoxically, plasma NEFA concentration decreased with
infusion of octanoate.

This decrease in arterial

concentration may be a reflection of several factors.

The

NEFA kit used apparently does measure octanoate as a fatty
acid since the site of octanoate infusion was the mesenteric

vein and resulted in an increase net release from the portal
drained viscera upon infusion and thus it is assumed that

the assay did not discriminate in analysis between
endogenous long-chain fatty acids and exogenous octonaote.

Fatty acid infusion was constant at 3.2 /xM of carbon per
minute, which was equivalent to 400 /xM octanoate per minute.
Correction for octanoate infusion showed that octanoate

tended to decrease net portal drained viscera uptake of NEFA

(P>.1) by 80 jumol/min.

Concomitantly, net hepatic uptake of

NEFA increased by 210 /xMol/min, which was equivalent to 50%
of the infusion rate.

Since the infusion rate was three

times greater than total splanchnic net uptake of NEFA and
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arterial NEFA concentrations decreased, it would appear that

octanoate is antilipolytic and mediated this observed
decrease in arterial NEFA concentration by some peripheral
mechanism.

Subsequent infusion of beta-hydroxybutyrate decreased
arterial NEFA concentrations an additional 34%.

A similar

effect was observed previously in diabetic untreated sheep,
although only a 10% decrease was observed in these
experiments (21).

Beta-hydroxybutyrate has been shown to

inhibit hormone-sensitive lipase and decrease adipose
release of NEFA (9).

It would appear that antilipolytic

effects of both octanoate and beta-hyroxybutyrate are

separate mechanisms, since their infusion together resulted

in a greater percent decrease than either by octanoate
alone, from the previous infusion period, or by betahydroxybutyrate as reported by Heitmann and Fernandez (21).

Hepatic NEFA extraction (46) and subsequent oxidation
(11) have been shown to be dependent on portal concentration

of NEFA.

Hepatic NEFA extraction was more than doubled,

even though arterial concentration was decreased by the

infusion of octanoate.

Since endogenous fatty acids are

predominately long chain fatty acids of 16 to 18 carbons
(36) and octanoate is 8 carbons, it would appear that
hepatic extraction may be dependent on moles of carbon

oxidized and not moles of substrate.

Subsequent infusion of
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beta-hydroxybutyrate did not affect hepatic NEFA extraction
ratios.

Previous work (21) with endogenous fatty acids has

shown beta-hydroxybutyrate to be more efficacious in
lowering hepatic extraction ratios in normal, fed sheep.

In

addition, beta-hydroxybutyrate decreased hepatic extraction
in alloxan-diabetic ewes being infused with oleate (39).

Diabetes resulted in portal drained visceral fluxes of
both acetoacetate and beta-hydroxybutyrate similar to that
reported previously for untreated, diabetic ewes (21).

Interestingly, octanoate caused decreased portal-drained
visceral release of beta-hydroxybutyrate, which also was
observed in untreated, diabetic ewes (21).

Beta-

hydroxybutyrate infusion restored alimentary ketogenesis,
but not nearly to the level observed in the control period.
Conversely, beta-hydroxybutyrate decreased net portal

drained visceral uptake and net hepatic release of
acetoacetate.

A similar effect was observed previously for

acetoacetate fluxes in these tissues (21), and may be
attributed to differences in localization of beta-

hydroxybutyrate dehydrogenase between the two tissue beds
(29).

Hypothetically, rumen epithelial and intestinal

tissue could extract acetoacetate and convert it to beta-

hydroxybutyrate in the mitochondria to help alleviate the
highly reduced state.

A decrease in ketogenesis by this

tissue could result in a decreased acetoacetate uptake.
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Alternatively, acetoacetate may be used for energy by these
tissues and an impaired utilization as observed in human
skeletal muscle (4) could also result in a decreased net

uptake

Net hepatic beta-hydroxybutyrate release was not

affected by any treatment (P>.1), although it did appear to

increase with time.

The lack of an effect is interesting

since net NEFA uptake was decreased by beta-hydroxybutyrate
infusion.

In contrast, beta-hydroxybutyrate decreased both

net hepatic uptake of NEFA and release of beta-

hydroxybutyrate when oleic acid was being infused (39).
Octanoate was more ketogenic than long-chain fatty acids in

hepatocytes from fasted rats (18).

In addition, palmitate

was oxidized less and esterified more than was octanoate in

rats (18,33).

Since ruminant liver has less fatty acid

synthesis activity than rat liver (26), octanoate may not be
subject to elongation and subsequent esterification as seen

in the rat liver (18).

Octanoate would then appear to be

subject to oxidation and ketogenesis to a greater extent in
ruminant liver and may partially explain why ketogenesis did
not decrease although hepatic NEFA uptake decreased when
beta-hydroxybutyrate was infused.

Carnitine is required for long-chain fatty acid
transport into the mitochondria (reviewed in 8,13) and
carnitine supplementation has been shown to increase

ketogenesis, in vivo (1), and, in vitro (16,17).

Lack of
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any observed effect of carnitine infusion on NEFA uptake and

subsequent ketogenesis is may be due to octanoate being
metabolized independent of carnitine mediated transport
mechanism (33,35).

Brass and Hoppel (12) correlated acid-soluble

acylcarnitine/carnitine ratio to plasma beta-hydroxybutyrate
concentration.

In several studies in sheep and cattle

(reviewed by 40), acetyl-carnitine is the predominant, but
not exclusive, acid-soluble acylcarnitine.

Propionyl-

carnitine is believed, but has not been demonstrated, to be

the other predominant carnitine ester in ruminants (41).

In

ketotic, lactating dairy cows, blood carnitine
concentrations increased threefold, without an observed

increase in hepatic carnitine concentrations (20).

Infusion

of beta-hydroxybutyrate in this work tended to increase
arterial plasma free carnitine concentrations (P<.1),

without a significant change in acid-soluble acylcarnitine
concentrations.

In addition, conversion of the ketone body

to its carnitine ester would involve a CoA ester

intermediate and activity of beta-hydroxybutyrate synthetase

has been speculated but not demonstrated in rumen tissues
(37).

Acetoacetate, via activation by acetoacetyl-CoA

synthetase, has been shown to contribute carbons for hepatic
lipogenesis in rats (19), but ruminants have low hepatic
lipogenic capacity (26) and may not have appreciable amounts
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of this enzyme.

A reversal of acylcarnitine hydrolase is

unlikely since activity of this enzyme was not detected in
sheep liver (43).

If hepatic carnitine pools had sufficient

time to equilibrated with the plasma pools, it would appear
with this data and the lack of mechanisms to activate ketone

bodies to their CoA ester that infused beta-hydroxybutyrate
did not bind and limit free carnitine pools.

An alternate

hypothesis for hepatic autoregulation may be that betahydroxybutyrate moderates hepatic carnitine concentrations,
although no significant hepatic free carnitne flux was

observed.

It has been observed previously that accumulation

of long chain fatty acyl CoA in hepatocyte may decrease

carnitine palmitoyl transferase affinity for carnitine, and
the subsequent accumulation of carnitine in ketotic liver

may be to overcome this effect (13).

A slight decrease in

hepatic carnitine concentrations could result in a decrease

in mitochondrial transport of long-chain fatty acids.
Although the liver is believed to be the predominant

site of the final step in carnitine synthesis because it
converts gamma-butyrobetaine to carnitine (reviewed by 25),

no significant carnitine flux was observed.

Hepatic vein-

portal vein differences for carnitine were reported

previously for untreated, diabetic sheep only after they had
been feed-restricted for 10 days , but net hepatic flux
rates for carnitine were not measuered (42).

A net release
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of free carnitine has been shown from the exercised leg of

humans, but no significant flux of free carnitine or acidsoluble carnitine was demonstrated across portal-drained

visceral or hepatic tissues (44).

Excretion of carnitine is

predominantly by urine in non-lactating animals, and has
been shown to be 300 )imol/day in man (13).

Assuming a

similar urinary excretion rate for ewes, hepatic release of
carnitine would have been less than 0.2 ^tMol/min.
Determination of such a small flux proved to be more

difficult than our protocol would allow.

In addition,

infusion of carnitine did not result in significant hepatic
uptake of carnitine, although arterial concentrations

exceeded the Kjn for transport of 500 /iM (8). Lack of an
effect on hepatic carnitine uptake by supraphysiological

carnitine infusion would suggest limited uptake ability by
the liver.

Carnitine infusion did increase net hepatic uptake of
glucagon and extraction ratio.

Intravenous carnitine

supplementation has been shown previously to increase blood
ketone body and decrease blood NEFA concentrations (1).

Hepatic carnitine uptake and subsequent NEFA uptake and
metabolism is assumed in that study to explain the observed
effects.

Carnitine supplementation more appropriately may

affect hepatic NEFA metabolism through glucagon.

Although

our carnitine infusion resulted in supraphysiological
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concentration of free carnitine in the plasma, it is the
only known report relating carnitine supplementation and the
effects on glucagon.

In addition, arterial concentrations

of glucagon did not decrease, nor did portal-drained
visceral release increase concomitant to the increased

hepatic uptake of glucagon.

This could mean a peripheral

effect of carnitine infusion that resulted in a concomitant

decreased uptake of glucagon in these tissues.

Further

research is warranted to verify these effects.

Insulin-dependent mechanisms of autoregulation have
been described previously (21).
regulation is twofold.

The premise of this

Ketone bodies have been shown to

stimulate pancreatic release of insulin (31), which in

accordance with bihormonal theory of regulating hepatic

fatty acid metabolism, should decrease ketogenesis (34).

Additionally, beta-hydroxybutyrate at ketotic concentration,
positively can affect insulin binding to its respective
receptor in lymphocytes (32) and may affect similarly
hepatocytes (21).

Mechanisms independent of insulin action

are believed to be peripherally mediated mechanisms.

Ketone

bodies have shown to inhibit hormone-sensitive lipase in
adipose tissue (9), which would subsequently decrease NEFA
availability for hepatic ketogenesis.

This data, in

accordance with a previous study (39), suggests that an
hepatic autoregulatory mechanism may exist.

Differences in

87

net hepatic release of ketone bodies during beta-

hydroxybutyrate infusion between this study and previous

work with oleate (39) indicate that carnitine may be
involved in the mechanism.

Increases in free carnitine

concentrations with beta-hydroxybutyrate infusion may
decrease available carnitine for hepatic long-chain fatty
acid oxidation, although a peripheral efflux of carnitine
can not be discounted by this study.

Additionally, the

observed effect of carnitine infusion on net hepatic
glucagon uptake was unexpected and does not appear to have
been observed previously.

It must be emphasized that these

observations were made with animals metabolizing exogenous
fatty acids that are not typically found, in vivo.

It would

be beneficial to repeat this study in animals not
supplemented with exogenous fatty acids and also in animals

supplemented with exogenous oleate.

Additionally,

interrelationships between carnitine and ketone body
metabolism have not been studied extensively in ruminants,
but a more thorough knowledge may be beneficial to

understanding homeorhetic mechanisms involved in regulating

hepatic metabolism during lactation, pregnancy, and fasting.
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CHAPTER IV

EFFECTS OF BETA-HYDRGXYBUTYRATE AND CARNITINE
ON HEPATIC ENDOGENOUS FATTY ACID METABOLISM

AND KETOGENESIS IN ALLOXAN-DIABETIC EWES
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ABSTRACT

A possible insulin-independent regulatory mechanism of
hepatic ketogenesis was studied in ewes surgically
catheterized in hepatic (H), portal (P), mesenteric (M), and
femoral (V) veins, and femoral artery (A). Six experiments
were conducted on 3 ewes made diabetic with alloxan (.05g/kg
bw, iv).

Euglycemia was maintained with daily insulin

injections (Iletin-100, "30 lU/d) until 3 d prior to
experiments, when injections were withheld to induce
ketosis.

Experiments consisted of 3 infusion periods: (1)

p-aminohippurate (PAH, 1.5% @ .764 ml/min) infusion into M
(Control); (2) PAH as in (1) and i3-hydroxybutyrate (BOHB, .4

mg/kg^/'^) into V; and (3) PAH and BOHB as in (2) and Lcarnitine (C, 1.18 mM/min) into V.

For each period, each

infusate was allowed to equilibrate for 1 h and then 3 blood
samples were taken simultaneously from H, P, and A at 15

minute intervals and analyzed for BOHB, acetoacetate (ACAC),
non-esterified fatty acids (NEFA), glucose and PAH.

P blood

flow was 2.1 1/min and 84% that of H, and was not affected

(P>.1) by infusate.

Relative to control, BOHB decreased

(P<.01) NEFA arterial concentrations (1223 to 572 /xmol) and

hepatic (238 to 66 jumol/min) and total splanchnic (216 to 71
/Limol/min) net uptakes.

BOHB increased ACAC arterial

concentrations (223 to 508 /nmol, P<.01) and decreased (P<.1)
hepatic (-3 to -81 Minol/min, P<.1) (i.e., decreased
ketogenesis) and total splanchnic (33 to -29 jumol/min)
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release.

BOHB had no effects on hepatic BOHB flux.

Carnitine had no effect on any parameters measured.

According to this data, BOHB may regulate ketogenesis as
observed by decreased hepatic NEFA uptake and ketogenesis to
ACAC, a major ketone product, but paradoxically had no
effect on BOHB production.

Carnitine in contrast had no net

effect on hepatic ketogenesis nor NEFA uptake, suggesting

that it may not be extracted by the liver in quantities
sufficient to counteract observed effects of BOHB.
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INTRODUCTION

Regulation of hepatic ketogenesis is primarily
moderated through the hormones glucagon and insulin (32).

Glucagon has been shown to affect NEFA availability for

hepatic oxidation and subsequent ketogenesis in most species
(33), including ruminants (10).

Glucagon has been shown

also to affect hepatic ketogenesis within the liver in sheep
(10), probably through regulation of acetyl-CoA carboxylase
(44).

However, within the hepatocyte, insulin appears to be

the more potent hormone in regulation in ruminants (10).
Since insulin concentrations may not be sufficient to
regulate NEFA oxidation and ketogenesis in diabetics and
during lactation (27), it would seem that alternate

mechanisms may exist for regulation.
Beta-hydroxybutyrate has been shown to stimulate

insulin pancreatic secretion (28) and to restore insulin
binding to near normal under hypoinsulinemic conditions in
culturered lymphocytes (30).

Ketone bodies have been

implicated in decreasing NEFA concentrations in several

species (5,6,19,22), which in turn would limit hepatic
substrate availability for oxidation and ketogenesis (34).
Hepatic NEFA extraction ratios and possibly ketogenesis are
depressed in alloxan-diabetic sheep and in normal animals

infused with beta-hydroxybutyrate (19), suggesting that an
hepatic mechanism may exist for autoregulation of
ketogenesis independent of insulin.

In addition, beta-
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hydroxybutyrate has been shown to decrease hepatic

ketogenesis from oleate, but not octonoate infusions (39;see
Chapter 3).

Since oleate and octonoate are metabolized by

similar enzymes of beta-oxidation, but long-chain fatty
acids reguire carnitine for transport (31), this difference
in regulation between these substrates suggest a possible
interaction with carnitine mediated transport systems.

In

addition, carnitine metabolism is not well established for
ruminants, and it would of benefit to understand carnitine
metabolism as it relates to ketosis.

This study was thus designed to better understand
possible insulin-independent autoregulary mechanisms for

hepatic ketogenesis using alloxan-diabetic sheep and

measuring flux rates across the portal drained visceral,
hepatic and total splanchnic tissue beds, and hindquarter
venoarterial differences for acetoacetate, betahydroxybutyrate, non-esterified fatty acids, free carnitine,

short-chain acylcarnitine, and glucagon.

An understanding

of these metabolites, in vivo, and effects of subsequent

infusion of beta-hydroxybutyrate and L-carnitine may explain
possible mechanisms of insulin-independent regulation of
hepatic ketogenesis.
MATERIALS AMD METHODS

Six experiments were conducted on three non-pregnant,
non-lactating, alloxan-diabetic ewes weighing 55 to 65 kg.
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Animals were housed individually in 1.8 X 3.0 m indoor pens
with ambient temperature maintained between 19 and 25°C and
under natural lighting.

Commercially prepared alfalfa

pellets were fed in two daily aliquots of 400 g at 0800 and
1700 h.

Water and trace mineralized salt were provided ad

libitum.

Animals were accustomed to laboratory personnel

prior to any experimentation and no restraint was required
for sample collection.

Catheters were surgically positioned into mesenteric,

hepatic, portal and femoral veins, and femoral artery of

each animal (see appendix 1 for diagrams), as described by
Katz and Bergman (24) and modified by Zanzalari et al. (47).
Due to concerns over catheter patency, the mesenteric artery
that ran parallel to catheterized mesenteric vein was also

catheterized as an alternate artery sampling site.

Ten days

following surgery, each animal was made pharmacologically
diabetic with a single intravenous dose of alloxan (Sigma
Chemical Co.) at 50 mg/kg body weight (19) between 1300 and
1700 h.

On the following day, glucose was monitored to

determine if diabetic state was established.

Animals

determined to be diabetic then received daily subcutaneous
doses of insulin (Iletin NPH-100, "40 U/d) at 1700 h to

reestablish and maintain euglycemic conditions (2.5 to 3.5
mM).

Insulin was withheld 3 d prior to the experimental
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date to establish a ketotic state and allow for the study of
insulin-independent effects.

On the experimental day, jugular catheters were
inserted prior to experimentation.

Animals were subjected

to consecutive infusates superimposed over three time
periods (see Figure 4.1).

Each period was two hours in

length, allowing one hour for equilibration of each

additional infusate and one hour for collecting samples.
The equivalence of a 30 minute infusion for each new

infusate was pulsed into the infusion site at the initiation
of each period.

The control period began at 0800 h with

para-aminohippurate (PAH, 1.5% w/v, Eastman-Kodak Co.) being
infused into mesenteric vein at 0.764 ml/min (Model
Harvard Apparatus).

,

The beta-hydroxybutyrate period

followed with infusion into the femoral vein at 1.18 mM/min
of dl-beta-hydroxybutyrate (1.6 M solution, Sigma Chemical
Co.) which corresponds to a rate similar to maximum

utilization in diabetic sheep (4).

Finally, the carnitine

period consisted of 1-carnitine (Sigma Chemical Co.) being
infused into the femoral vein at a rate equimolar to the
beta-hydroxybutyrate infusion.

Sampling within each period

consisted of three blood samples taken at 30 min intervals

simultaneously from the hepatic (11 ml) and portal (11 ml)
veins and femoral artery (15 ml).

Each sample was

immediately immersed in an ice water bath and assayed as

Txme

Start BOHB infusion

Sample lA, IH, IP
Sample 2A, 2H, 2P
Sample 3A, 3H, 3P

Start PAH infusion

Comment

FIGURE 4.1

360

330

300

240

180

FATTY ACID STUDY

OUTLINE OF INFUSION PERIODS FOR ENDOGENOUS

Sample 7A, 7H, 7P
Sample 8A, 8H/ 8P
Sample 9A, 9H, 9P

Start Carnitine infusion

Cam

245

BOHB

-Infusates—

210

PAH

Sample 4A, 4H, 4P
Sample 5A, 5H, 5P
Sample 6A/ 6H/ 6P

125

120

90

60

0

(min)

100
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described below (see Appendices for each assay protocol,

listing appears on contents page).

Between experimental

days and throughout all experimental periods, catheter
patency was maintained with 6% NaEDTA solution.

After all

sampling was completed, plasma was separated and immediately
frozen in individual aliquots for future analysis of

glucagon, carnitine, and insulin.

All other analysis were

performed on the day of the experiment.
Acetoacetate, beta-hydroxybutyrate, and PAH values for
whole blood and NEFA, glucagon, and free and acid soluble

acylcarnitines values for plasma were determined for all

samples.

Hematocrits, blood glucose, and plasma insulin

values were monitored only on femoral artery samples.
Plasma percent was determined by subtraction of the
hematocrit value from 1.

A one milliliter aliquot of whole blood was analyzed
for PAH as described by Kaufman and Bergman (25).

An

additional 2 ml of whole blood was deproteinated in an equal
volume of cold 1 M perchloric acid as discussed previously

(19) and analyzed for acetoacetate and beta-hydroxybutyrate
by the spectrophotometric, enzymatic method of Williamson

and Mellanby (46).

Glucose was determined by analyzing 200

/il of whole blood with a commercial spectrophotometric

enzymatic kit (Sigma Chemical Co.).

Non-esterified fatty

acids were determined by analyzing freshly isolated plasma
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with the commercially available NEFA-C kit (Wake Chemical
Co.)•

Insulin and glucagon were measured by a standard double

antibody radioimmunoassay technique (48).

The first insulin

antibody was guinea pig anti-bovine insulin (Research
Products International) and the second was anti-guinea pig

GIG (Miles Laboratories Inc.).

The first glucagon antibody

was rabbit anti-glucagon antibody (R. H. Unger, University
of Texas Health Sciences Center, Dallas) and the second was

anti-rabbit GIG (Research Products International).

Free and

acid-soluble acylcarnitine concentrations were determined

radioenzymatically (11) as modified by Sachan et al. (38)

using ^^C-acetyl coenzyme A (NEN-Dupont) .
Blood flow rates were determined by dividing the rate

of PAH infusion (optical density units/min) by the

venoarterial PAH concentration differences (optical density
units/L) across each specific tissue.

Blood flow rates for

hepatic and portal veins were measured directly and the
hepatic arterial flow represented the difference between the

two known values.

Plasma flow rates were determined by

multiplying blood flow rates by plasma percent .
The equations for net flux calculations have been

published previously (21; also presented in Appendix 2) and
are simply the venoarterial concentration differences across

the tissue multiplied by the respective blood flow rate.
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Positive values are indicative of a net release, whereas

negative values indicate a net uptake, of the metabolite by
that tissue.

These values do not represent unidirectional

flux, and should not be interpreted as such.

Hepatic

extraction ratios were calculated as the fraction of the

metabolite taken up by the organ relative to the total

concentration presented to the organ per unit time.
Significant differences between treatments would indicate
intraorgan effect independent of blood flow and
concentrations.

Statistical analysis involved comparing subsequent
means of consecutive treatments without inference to any
other treatments.

Means were separated by an unpaired t-

test within and among sheep and significance was considered
at the levels of P < 0.1, P < 0.05, and P < 0.01.
RESULTS

Portal and hepatic blood flow rates, portal to hepatic

ratio, and plasma percent values appear in Table 4.1.
Subsequent treatments had no significant affect on portal
and hepatic blood flow rates, nor on plasma values.

Carnitine infusion increased the portal to hepatic ratio
from 0.80 to 0.87 (P<.05), meaning that a greater percentage

of the blood coming to the liver was from that draining the
the guts as opposed to recirculated arterial blood.

This

TABLE 4.1

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusions on blood flow rates,
portal hepatic flow ratios, and plasma percent in alloxan-diabetic ewes.^*

Treatment

Portal
Vein

Hepatic

Blood
Flow

Blood

Portal/
Hepatic

Plasma

Flow

Ratio

Percent

2.9
± .18

+

Vein

—(1/min)—
Control

2.4
+

.17

+

.17

BOHB

2.0

Carnitine

2.5
+

2.0
+

.12

.17

+

.14

75

.02

± 1

.80

77

.03

± 1

_ _ **

2.3
+

.84

+

.87

77

.02

± 1

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

Significantly different from the preceding infusion period, P < .1.
**

Significantly different from the preceding infusion period, P < .05,

***

Significantly different from the preceding infusion period, P < .01,
o
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effect could be due to either treatment, or a mere

reflection of sampling effects over time.
Arterial NEFA concentrations, net flux rates, and

hindquarter venoarterial differences are presented in Table
4.2.

Hepatic-portal, hepatic-artery, and femoral vein-

artery differences are presented in Appendix 4 (Table A4.1).
Infusion of beta-hydroxybutyrate resulted in a 53% reduction
in arterial NEFA concentration (P<.01) despite a 68%

decrease in hepatic NEFA uptake.

Total splanchnic release

similarly was decreased by beta-hydroxybutyrate (P<.01).

Calculated hepatic extraction ratios for the control period
averaged 9 %, similar to that reported previously in
untreated, diabetic sheep (19).

Hepatic extraction ratios

were decreased by infusion of beta-hydroxybutyrate to 6%
(P<.01).

Subsequent infusion of carnitine had no further

effects on NEFA concentration or net fluxes.

Venoarterial

NEFA differences across the hindquarter represented only 4

of the 6 experiments due to catheter patency complications.
Beta-hydroxybutyrate and carnitine had no significant effect
(P>.1) on femoral vein-artery differences for NEFA.
Whole blood arterial concentrations, net fluxes, and

hindquarter venoarterial differences for acetoacetate and
beta-hydroxybutrate appear in Tables 4.3 and 4.4.
Venoarterial differences for splanchnic tissues are
presented in Appendix 4 (Tables A4.2 and A4.3).

Arterial

TABLE 4.2

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma NEFA
arterial concentrations, net flux rates, hepatic extraction percents, and hindquarter
venoarterial differences in untreated, alloxan-diabetic ewes. *

Hepatic

Portal
Drained

Artery

Treatments

Visceral

-(/iM)1223

Control

Hepatic

(%)

(/imol/min)
22

Extraction
Ratio

-210

9

± 0

Total

Femoral
Vein -

Splanchnic

Artery^•

(/imol/min)

-(/iM)-

-187

65

± 18

± 15

± 142

± 20

± 19

572

-5

— DO

6

— DO

44

±81

±7

± 10

± 1

± 11

± 12

425

-3

-49

7

-52

38

55

±4

± 9

± 1

± 9

± 11

BOMB

Carnitine
±

***

***

***

standard error of means. n = 18, 3 measurements on 6 ewes, unless column
noted otherwise.

^*

Means

+

^•

Means

+

*

Significantly different from the

preceding infusion period.

P < .1.

**

Significantly different from the

preceding infusion period.

P < .05.

***

Significantly different from the

preceding infusion period.

P < .01.

standard error of means. n = 12, 3 measurements on 4 ewes.

M
O
cr»

TABLE 4.3

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on acetoacetate
arterial concentrations, net flux rates, and hindquarter venoarterial differences in

untreated, alloxan-diabetic ewes.^*

Femoral

Portal

Arterial

Treatment

Drained
Visceral

Total

Hepatic

Splanchnic

— (jLimol/min)
Control

228

± 40

+

_„_***

508

BOHB

± 55

Carnitine

503
± 60

Means

+

Artery^•
-(/iM)-

36

-3

33

-44

11

± 18

± 17

± 7

*

-81*

52
+

Vein

-29

-34

± 31

± 18

26

± 36

92
± 15

-150

-58

-29

± 19

± 12

± 7

standard error of means. n = 18,

3 measurements on

6 ewes, unless column

noted otherwise.

^*

Means

*

Significantly different from

the

preceding infusion period.

P < .1.

Significantly different from

the

preceding infusion period.

P < .05.

different from the

preceding infusion period.

P < .01.

+

standard error of means. n = 12,

*** Significantly

3

measurements on 4 ewes.

H
o

TABLE 4.4

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on betahydroxybutyrate arterial concentrations, net flux rates, and hindquarter venoarterial

differences in untreated, alloxan-diabetic ewes.^*

Treatment

Arterial

Portal

Femoral

Drained
Visceral

Vein

BOHB

Carnitine

Splanchnic

(/xmol/min) —

--(AiM)-Control

Total

Hepatic

Artery^ *
-(MM)-

3218

261

917

1178

-325

± 520

±.91

± 142

± 188

± 57

7789

239

941

1180

-503

± 741

± 75

± 103

± 142

± 91

8098

85

810

896

-645

± 928

± 75

± 92

± 108

± 100

Means ± standard error of means, n = 18, 3 measurements on 6 ewes, unless column
noted otherwise.

Means ± standard error of means, n = 12, 3 measurements on 4 ewes.

Significantly different from the preceding infusion period, P < .1.
**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
o
(X)
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acetoacetate and beta-hydroxybutyrate concentrations were

228 and 3218 juM during the control period and increased more
than 2 fold, to 408 and 7789 /iM (P<.01) when betahydroxybutyrate was infused.

Portal drained visceral net

release of acetoacetate was not affected by any infusion
period.

Conversely, hepatic net uptake of acetoacetate

increased nearly 80 jumol/min with beta-hydroxybutyrate
infusion (P<.1).

Subsequent carnitine infusion had no

effect on net hepatic acetoacetate uptake, although hepaticportal differences were increased nearly 2 times, from -32

to -75 /iM (P<.05).

Due to effects of beta-hydroxybutyrate

infusion on net hepatic acetoacetate flux, total splanchnic
net acetoacetate flux appears to shift from a state of net

release of 33 /iM/min to a state of net uptake of 29 /tM/min
(P<.1), but may not be significant since neither of these

values were significantly diferent from 0.

Portal drained

visceral, hepatic, and total splanchnic net beta-

hydroxybutyrate releases were 261, 917, and 1178 /xmol/min

during the control period, and were not affected by any
subsequent infusate.

Plasma arterial glucagon concentrations, flux rates and

hindquarter venoarterial differences appear in Table 4.5.
Control arterial concentrations were 239 pg/ml and
subsequent treatments had no significant effect on arterial
concentrations and.

However, infusion of beta-

TABLE 4.5

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma
glucagon arterial concentrations, net flux rates, hepatic extraction percents, and
hindquarter venoarterial differences in untreated, alloxan-diabetic ewes. *

Treatments

Artery

-(/iM)Control

239

Portal

Hepatic

Drained
Visceral

Extraction
Ratio

Hepatic

(/xg/hr)
8.65

-2.10

(%)

Vein -

Splanchnic

Artery *

-(jLig/hr)-

(pg/ml)

5

6.55

-22

± 1.77

± 5

± 29

±2.07

± .52

± 1

229

4.91

-2.10

7

BOHB

Femoral
Total

2.81*
± .45

± .66

± .36

172

4.89

-2 10

9

2.78

± 11

± .93

± .41

± 2

± .84

± 34

Carnitine

± 1

-51

± 27

-19*
± 4

Means ± standard error of means, n = 18, 3 measurements on 6 ewes, unless column
noted otherwise.

Means ± standard error of means, n = 12, 3 measurements on 4 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
O
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hydroxybutyrate did tend to decrease net total splanchnic
release of glucagon (P < 0.1).

Although net hepatic uptakes

were identical for all treatments, net portal drained
visceral release may have decreased, resulting in the
decreased total splanchnic release.

Venoarterial

differences across the splanchnic tissues were not
significantly different from 0 and not affected by any
treatment (Appendix 4 Table A4.4).

No effect was observed

on hindquarter venoarterial differences with betahydroxybutyrate infusion.

Subsequent infusion of carnitine

tended to decrease hindquarter venoarterial diffences

(P<.1), suggesting a decreased hindquarter uptake of
glucagon, assuming that blood flow through this tissue was
not decreased, without a concomitant increase on total

splanchnic release nor a significant decrease in areterial
concentrations.

Arterial blood glucose and plasma insulin concentration
are summarized in Table 4.6.

Blood glucose concentrations

were elevated and not significantly affected by any

treatment.

Insulin concentrations were 13.4 /iU/ml during

the control period and were unaffected by

the treatments.

Insulin concentrations were significantly different from 0,
suggesting that these animals were not completely deficient
of insulin.

TABLE 4.6

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on arterial plasma

concentrations of free carnitine, acid-soluble acylcarnitine, glucose, and insulin in

untreated, alloxan-diabetic ewes.^*

Acid-soluble
Treatment

Free

acyl

Carnitine

carnitine

Glucose

(MU/ml)

(MM)
Control

BOHB

Carnitine

Insulin

22.7

17.2

9.2

13.4

± 2.9

± 1.6

± .3

± 1.6

18.1

18.2

9.0

13.8

± 2.3

± 1.2

± .2

± 1.7

.
^^

4605

± 144

"k k "k

555

± 66

8.7

14.6

± .2

± 1.7

1.

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05,

"kick

Significantly different from the preceding infusion period, P < .01
h-»
to
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Arterial concentrations for free and short-chain acylcarnitine are reported in table 4.6.

Arterial

concentrations for free carnitine in the control period are

slightly higher than those observed previously (15; see
Chapter 3).

Subseguent infusions of beta-hydroxybutyrate

had no effect on concentrations of free or acid-soluble

acylcarnitines.

Infusion of free carnitine, of course, did

significantly elevate both free and short-chain acylcarnitine concentrations.

Flux rates for both free and

short-chain acyl- carnitine were determined (see Appendix 4
Tables A4.6 and A4.8) and were not shown to be significant

from zero during any period for hepatic and total splanchnic
tissues.

Portal drained visceral uptake of acid-soluble

acylcarnitine was demonstrated upon infusion of carnitine

(P<.05), but may not be physiologically significant.
DISCUSSION

Arterial concentrations and net fluxes for NEFA,

acetoacetate, beta-hydroxybutyrate, non-esterified (free)
carnitine, acid-soluble carnitine, and glucagon were
measured in untreated, alloxan-diabetic ewes.

The study was

designed to evaluate the insulin-independent intrahepatic
regulation of hepatic fatty acid oxidation and ketogenesis
by beta-hydroxybutyrate and the possible role of carnitine
in this regulation.
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Presence of insulin in arterial samples was unexpected

since the animals had been made pharmacologically diabetic
with alloxan.

Previous reports (19) have suggested that the

small amounts of insulin that were measured in diabetic

animals (approximately 3 /iU/ml) could be due to cross-

reactivity of the insulin radio-immunoassay employed.
Values reported were 13-14 /iU/ml andd must have been due to

factors other than assay cross-reactivity.

However, these

concentrations were lower than those reported for normal

sheep (2). Previous work reported a three day withdrawal
from insulin was sufficient to establish an insulin-free
state (19).

The presence of insulin could be due to a lack

of alloxan establishing a complete insulin-deficient state,
although other ewes treated similarly in a separate set of
experiments were diabetic.

Alternatively, the withdrawal

period may not have been sufficient in length for these

animals to clear the daily insulin doses given prior to
experimentation.

Arterial concentrations of glucose, NEFA, acetoacetate,
and beta-hydroxybutyrate in our untreated, alloxan-diabetic

sheep were elevated relative to normal sheep (10,19,21), but

lower than those reported previously for diabetic sheep not
supplemented with insulin (19; also see Chapter 3).

Insulin

concentrations were less than that reported in normal

animals (2,21), and diabetic animals supplemented with daily
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insulin (19).

Thus, it would appear that these animals were

in an insulin-impaired state, but not in a completely
insulin-deficient state.

Beta-hydroxybutyrate infusion decreased arterial NEFA

concentrations, as observed previously in sheep (19), humans
(1,22), and dogs (6).

A proposed mechanism for

autoregulation of ketogenesis has involved the limitation of

available NEFA for hepatic uptake by beta-hydroxybutyrate
inactivating adipose hormone-sensitive lipase (5).
Venoarterial differences of NEFA across the hindquarter were
not significantly affected by infusion of beta-

hydroxybutyrate, implying that peripheral release may not be
affected by beta-hydroxybutyrate in ewes.

In contrast,

Dawes (12) demonstrated a decreased hindquarter NEFA release

with beta-hydroxybutyrate infusion.

Due to the nature of

the experimental design, and the method for measuring
hindquarter blood flow rates, net flux across the

hindquarters could not be measured for any treatment period.
Venoarterial differences alone are not informative as the

net flux (18).

A decrease in hindquarter NEFA flux would

result in decreased arterial NEFA concentration without a

decrease in venoarterial differences if rump flow decreased.
This is unlikely since blood flow rates across the

splanchnic tissue beds were not affected by treatment and
could only occur if cardiac output decreased.
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Alternatively, the hindquarters of normal steers is composed
predominantly of muscle, with less than 3% fat (3), and
muscle oxidizes NEFA, in addition to ketone bodies (23).

A

sparing of NEFA by ketone bodies following infusion of betahydroxybutyrate would decrease muscle utilization

concomitant to decreased adipose release of NEFA, which

could result in no net venoarterial difference for NEFA, but

increase venoarterial differences for beta-hydroxybutyrate,
which was not observed (P>.1).

Beta-hydroxybutyrate

decreased net hepatic NEFA uptake nearly 70%, which in turn,

passively decreased net total splanchnic uptake by 63%.
Alternatively, cardiac tissue can metabolize NEFA, but
recent reports have suggested that beta-hydroxybutyrate may
decrease cardiac beta-oxidation of NEFA (29,42,43).
Considering these points, the decrease in arterial NEFA
concentrations observed upon infusion of betahydroxybutyrate cannot be explained by this data.
Beta-hydroxybutyrate infusion did not decrease net

hepatic release of beta-hydroxybutyrate.

Ketogenesis was

not affected by beta-hydroxybutyrate infusion in diabetic,

untreated sheep reported by Heitmann and Fernandez (19), but

hepatic NEFA extraction ratios tended to decrease slightly,
although not significantly.

This previous study did

indicate that hepatic NEFA uptake or metabolism possibly was
impaired in diabetic, ketotic subjects as evidenced by
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suppressed hepatic NEFA extraction ratio relative to the

normal, fed control ewes.

Hepatic extraction in this study

was 9% in the control period, slightly lower than that
reported previously in diabetic sheep (19), and was
decreased nearly 33% by beta-hydroxybutyrate infusion.

The

lower NEFA extraction ratios in untreated, diabetic sheep
during the control period could be due to the accumulation

of ketones in these animals serving to regulate hepatic NEFA
uptake or metabolism.

The decrease in NEFA extraction

following beta-hydroxybutyrate infusion was not as dramatic
as that observed in normal, fed sheep (19), which also

supports this concept.

Hepatic extraction (45) and

subsequent oxidation (7) has been shown to be concentration

dependent in normal animals.

Fatty acid transport across

the cell plasma membrane has been suggested to be of first

order kinetics (41).

The decrease in hepatic NEFA

extraction ratios in untreated, diabetic sheep relative to
normal animals (19) could be due to a saturation of
transport systems since arterial NEFA concentrations are

elevated in diabetes.

Infusion of beta-hydroxybutyrate

decreased arterial concentrations of NEFA which should, if
NEFA transort was saturated, increase hepatic NEFA

extraction ratio.

However, beta-hydroxybutyrate infusion

resulted in a decreased hepatic NEFA extraction ratio.

Since beta-hydroxybutyrate infusion into untreated, diabetic
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sheep results in arterial NEFA concentrations 60% of that

observed in the control and no subsequent restoration of
NEFA extraction ratios to levels near those observed in

normal animals (19,21), it would appear that elevated ketone

body concentration due to either diabetes, or infusion, or
both, may impair NEFA transport

and/or metabolism.

Lack of a decrease in hepatic ketogenesis in alloxan-

diabetic sheep could be due to factors.

If autoregulation

has an hepatic mechanism, then diabetic animals may already
have an active homeorhetic mechanism suppressing ketogenesis
that may not be differentiated by subsequent betahydroxybutyrate infusion.

In addition, net flux is a

combination of both unidirectional uptake and release.
Concomitant decreases in both uptake and release of beta-

hydroxybutyrate could result in no effect on net hepatic

release.

Unidirectional hepatic beta-hydroxybutyrate uptake

and subsequent oxidation is questionable, since enzymes for
activation of beta-hydroxybutyrate to the coenzyme A ester
have not been reported in hepatocytes (37).
Hepatic acetoacetate flux has been shown to shift from

net release to net uptake (19), or as in this study, an

increase in net uptake following beta-hydroxybutyrate
infusion.

Acetoacetate may be a regulatory metabolite since

there was an observed change in its net flux following betahydroxybutyrate infusion.

Acetoacetate is taken up by the
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liver in normal animals (reviewed by 20), and subsequently
converted to beta-hydroxybutyrate by cytosolic beta-

hydroxybutyrate dehydrogenase (26).

Drackley et al. (13)

observed a decrease in acid-soluble products following
addition of acetoacetate to bovine hepatocytes.

In

addition, cytosolic acetoacetyl-CoA synthetase has been
suggested to exist in hepatocytes of rats (14) and
acetoacetyl-CoA can regulate beta-oxidation via inactivation

of acyl-CoA dehydrogenase (36) and ketogenesis via

inactivation of hydroxymethylglutaryl-CoA synthetase (29).
Increases in arterial acetoacetate concentrations due to
beta-hydroxybutyrate infusion could result in the increased

acetoacetate uptake.

In this experiment, net hepatic

acetoacetate uptake increased by 40 fold.

The observed

increase in arterial concentration of acetoacetate is
probably due to extrahepatic conversion from beta-

hydroxybutyrate, although no effect on hindquarter
venoarterial differences were observed for acetocaetate or
beta-hydroxybutyrate.

Due to the lack of a beta-hydroxybutyrate

autoregulation in animals utilizing octanoate as the primary
fatty acid substrate, but presence of a possible mechanism
in animals utilizing oleate, it has been suggested that
carnitine may be involved (39).

Though speculative, it was

proposed that beta-hydroxybutyrate may decrease the
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available carnitine for mitochondrial long-chain-fatty acid
transport.

If acylation of carnitine was the mechanism and

the carnitine pools of the liver were in equilibrium with
the blood, then an increase in short-chain acylcarnitine
would be expected following infusion of betahydroxybutyrate.

This was not observed in this nor a

previous experiment, (see Chapter 3).

The lack of a

significant effect on net hepatic free carnitine flux

following beta-hydroxybutyrate infusion suggests no effect
on free carnitine available for hepatic NEFA oxidation.

Hepatic carnitine levels are elevated in diabetic sheep
nearly 28-fold (40) and may not be limiting for NEFA

oxidation.

Although hepatic concentrations of carnitine and

carnitine esters were not measured in this study, it would
appear, based on this and previous work, that a lack of

available carnitine for NEFA transport is not involved in
the mechanism of regulation.

A recent report by Drackley et al. (13) has shown that

beta-hydroxybutyrate decreased NEFA oxidation to CO2 and
acid soluble products, i.e. ketone bodies, in cultured
hepatocytes.

Such an effect would appear to be due to

either an interference in mitochondrial transport, since
this step is considered to be rate limiting (34), or a

decrease in beta-oxidation.

Although beta-hydroxybutyrate

did not inhibit mitochondrial carnitine acyltransferase
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isolated from rats (16), data is lacking on its effect in
ruminants, which may have evolved such a mechanism.

Differences between ruminants and other species in
mitochondrial transport of NEFA appear to exist since
methylmalonyl-CoA has been shown to regulate mitochondrial

carnitine palmitoyl-transferase (9), whereas this mechanism
has been shown to be nonexistent in rats (35).

Similar to a previous work (see Chapter 3), no

significant carnitine flux was observed in any treatment
period.

The

for carnitine uptake is approximately 500 /xM

(8). Since the concentration of carnitine exceeded the Kju,
and no significant flux was observed, it would appear that
the liver has limited hepatic carnitine transport systems.
Glucagon infusion into sheep has been shown to increase

hepatic ketogenesis and arterial NEFA concentration (10).
Beta-hydroxybutyrate infusion resulted in a decreased total-

splanchnic release of glucagon in this study, which could
have affected hepatic ketogenesis and arterial NEFA
concentrations.

However, no effect was observed on arterial

glucagon concentrations, nor upon hepatic glucagon uptake

with infusion of beta-hydroxybutyrate.

A previous report

(see Chapter 3) demonstrated an increase in hepatic uptake
of glucagon upon infusion of carnitine.

Contrary to the

previous work, glucagon uptake by the liver was not
significantly increased by carnitine infusion.

The observed
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increase in hepatic uptake of glucagon in the previous study
may be due to interaction of carnitine with octanoate in
that study, and not the result of carnitine infusion.

Data presented here supports the concept of an

autoregulatory mechanism of hepatic ketogenesis demonstrated
by a decrease in hepatic NEFA extraction with infusion of

beta-hydroxybutyrate independent of any effects in hepatic
glucagon metabolism.

Although knowledge of plasma membrane

fatty acid binding proteins is limited and regulation of

their function has yet to be fully explained, a possible

mechanism may be a competitive inhibition of NEFA transport
by acetoacetate.

The pyruvate:lactate transporter has high

affinity for acetoacetate, and may be competively inhibited
by this compound (17). Alternatively, acetoacetate may
regulate enzymes of beta—oxidation and ketogenesis as
acetoacetyl-CoA.

This would explain increased acetoacetate

uptake concomitant to the decreased hepatic NEFA extraction.
A second, although unlikely mechanism, may be a direct

interaction of ketone bodies with carnitine palmitoyltransferase I.

It is obvious from this data and other data

discussed, that further in vitro research may help explain
the observed phenomena.

A better understanding of hepatic

autoregulation of ketogenesis may prove useful in preventing
ketosis due to lactation, pregnancy, or diabetes.
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Equations for the determination of net fluxes
and hepatic extraction ratio

Portal drained viscera flux =

Portal flow * (ConcentrationpQj-tal ~

Concentrationartery)
Hepatic flux =

Portal flow * (ConcentratioHhepatic ~
ConcentratioHpoj-tal) + Arterial flow *

(ConcentratioHhepatic "

ConcentratioHaj-tery)
Total splanchnic flux =

Hepatic flow * (Concentrationhepatic ~
Concentration^rtery)
Hepatic Extraction Ratio =
Hepatic flux/(Arterial flow *

Concentrationartery + Portal flow *
Concentrationpoj-tal)

APPENDIX 3

TABLE A3.1

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on blood
plasma NEFA venoarterial differences in untreated, alloxan-diabetic ewes. *

Hepatic
Treatment

Portal
Vein -

Vein -

Hepatic

Portal

Artery

Vein -

Vein

Artery

(MM;
Control

Octanoate

-89

-148

-237

± 42

± 22

± 40

. ^***
-436

-157

± 35

± 22

^ ^^ ^^*

279

± 28
BOHB

Carnitine

194

-287

- 94

± 18

± 21

± 13

238

-279

- 41**

± 28

+ 25

± 14

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

Significantly different from the preceding infusion period, P < .1.

Significantly different from the preceding infusion period, P < .05.

*** Significantly different from the preceding infusion period, P < .01.

(-•
U)

Ol

TABLE A3.2

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on blood

plasma NEFA arterial concentrations and uncorrected net flux rates in untreated,
diabetic ewes.^*

Hepatic

Portal

Drained
Treatment

Visceral

Arterial

Hepatic

(%)

—(MM) —
Control

Octanoate

2028

-154

+ 140

± 62
***

1603*

330

± 17

± 162
r- ^

1056

BOHB

Carnitine

*

251***

***

Total

Splanchnic

(Mmol/min)

-416

.09

-570

± 53

± 1

± 86

-629**

.22

-299**

± 67

± 2

± 63

-424**

.21

-173*
± 28

± 93

± 15

± 34

± 2

942

276

-366

.20

- 90

± 73

± 19

± 34

± 2

± 24

Means ± standard error of means, n — 15, 3

*

Extraction
Ratio

measurements on 5 ewes.

Significantly

different from

the preceding infusion period, P < .1.

Significantly

different from

the preceding infusion period, P < .05.

Significantly

different from

the preceding infusion period, P < .01.
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TABLE A3.3

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on blood
acetoacetate venoarterial differences in untreated, alloxan-diabetic ewes.
Hepatic

Treatment

Hepatic

Portal

Vein -

Vein -

Portal

Vein -

Artery

Vein

Artery

(MM) —
Control

Octanoate

20

35

± 14

± 23

*

-32

29

33

± 6

± 19

± 18

***

BOHB

Carnitine

1.

-6

± 12

—5

-1

-2

± 5

± 6

± 8

2

15

6

± 10

± 10

± 17

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

Significantly different from the preceding infusion period, P < .1.
**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
M

TABLE A3.4

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on^blood
beta-hydroxybutyrate venoarterial differences in untreated, alloxan-diabetic ewes.
Hepatic
Vein -

Vein Portal

Artery

Vein

Portal

Treatment

Hepatic
Vein -

Artery

(MM)
Control

Octanoate

BOHB

Carnitine
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337

471

± 47

± 53

± 44

-13''

704

± 60

± 101

± 81

142

656

798

± 112

± 90

± 115

-24

807

783

± 157

± 184

± 113

1.
*

**

***

**

***

716

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

Significantly different from the preceding infusion period, P < .1.
Significantly different from the preceding infusion period, P < .05.
Significantly different from the preceding infusion period, P < .01.
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TABLE A3.5

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on blood

plasma glucagon venoarterial differences in untreated, alloxan-diabetic ewes. *

Hepatic

Hepatic

Vein -

Vein Portal

Artery

Vein

Artery

Portal

Treatment

Vein -

■(pg/ml)
Control

±

± 9

Octanoate

±

±

±

± 10

Means ± standard error of means,

±

6

11
49

n = 12,

±

4
47

68

8
38

27

76
± 13

Carnitine

±

6
38

76

± 15
BOHB

15

32

47

12

**

6

21
±

9

3 measurements on 4 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.

M
U)

TABLE A3.6

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on blood
plasma free carnitine net flux rates in untreated, alloxan-diabetic ewes. *

Portal

Treatment

Control

Octanoate

BOHB

Drained Visceral

Splanchnic

0.49

0.26

0.75

± .37

± .61

± .62

0.20

-0.11

0.09

± .29

± .37

± .47

0.30

0.16

0.46

± .41

± .38

± .33

Carnitine

Total

Hepatic

-203.13

-54.98

± 125.88

± 129.91

-258.12**
± 95.61

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
o

TABLE A3.7

Effects of subsequent ootanoate, beta-hydroxybutyrate,
5^°°'"
plasma free carnitine venoarterial differences in untreated, alloxan-diabetic ewes.
Hepatic
Portal
Vein -

Treatment

Artery

Vein Portal
Vein

Hepatic
Vein -

Artery

(AIM)
Control

Octanoate

BOHB

0.17

0.08

0.25

± .17

± .21

± .18

0.19

-0.10

0.09

± .24

± .22

± .29

0.15

0.10

0.24

± .21

± .18

± .22

-68.78

39.27

-108.05

± 49.88

± 55.25

± 44.91

**

Carnitine

1.
*

**

***

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

Significantly different from the preceding infusion period, P < .1.
Significantly different from the preceding infusion period, P < .05.
Significantly different from the preceding infusion period, P < .01.

H*

TABLE A3.8

Effects of subsequent octanoate, beta-hydroxybutyrate, and L-carnitine infusion on bl^od
plasma acid-soluble acylcarnitine net flux rates in untreated, alloxan-diabetic ewes.
Portal

Treatment

Control

Octanoate

BOHB

Carnitine

Drained Visceral

Total

Hepatic

Splanchnic

-3.30

-5.61

± 5.07

± 4.77

± 1.85

-1.45

-0.45

-1.90

± 1.30

± 1.11

± 1.65

-0.10

-0.74

-0.84

± .96

± 1.08

± 1.41

-29.60

-104.43

-134.03

-2.31

± 75.04

± 80.66

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

1+

o

Significantly different from the preceding infusion period, P < .05.

*** Significantly different from the preceding infusion period, P < .01.

t-*
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TABLE A3.9

Effects of subsequent octanoate, beta-hydroxybutyrate, and ^"carnitine infusion on bloo^
plasma acid-soluble acylcarnitine venoarterial differences in untreated, alloxan diabetic
___ _

1•

ewes.

Hepatic
Portal

Vein -

Treatment

Artery

Vein Portal
Vein

Hepatic
Vein -

Artery

(MM)
Control

Octanoate

BOHB

Carnitine

-0.07

-2.00

-2.07

± 2.49

± 2.46

± .77

-1.32

-0.08

-1.40

± 1.11

± .63

± 1.08

0.18

-0.28

-0.11

± .54

± .76

± .80

-67.25

-44.31

-111.57

± 46.69

± 36.93

± 59.93

1.

Means ± standard error of means, n = 15, 3 measurements on 5 ewes.

*

Significantly different from the preceding infusion period, P < .1.

** Significantly different from the preceding infusion period, P < .05,
*** Significantly different from the preceding infusion period, P < .01
W
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TABLE A4.1

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma NEFA
venoarterial differences in untreated, alloxan--diabetic ewes.^*

Hepatic
Treatment

Portal

Vein -

Hepatic

Vein -

Portal

Vein -

Artery

Vein

Artery

(UK)
Control

BOMB

Carnitine

13

-107

-95

± 10

± 12

± 11

-2

-39

-39

± 5

± 7

± 7

-3

-31

-34

± 3

± 6

± 7

_ _ ***

1.

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
(ji

TABLE A4.2

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood acetoacetate
venoarterial differences in untreated, alloxan-diabetic ewes.

Hepatic

Treatment

Hepatic

Portal

Vein -

Vein -

Portal

Vein -

Artery

Vein

Artery

-(/iM)Control

18

0

18

± 5

± 7

± 7

22

BOHB

Carnitine

-10'

-32'

± 14

: 15

± 16

45

-75

-29

± 6

± 9

± 6

**

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

*** Significantly different from the preceding infusion period, P < .01.

^
a\

TABLE A4.3

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood beta-

hydroxybutyrate venoarterial differences in untreated, alloxan-diabetic ewes.

Hepatic
Vein Portal

Hepatic

Vein -

Artery

Vein

Artery

Portal
Treatment

Vein -

(MM)
Control

BOHB

Carnitine

110

347

457

± 40

± 62

± 77

133

394

527

± 43

± 59

± 71

22

± 38'

403

425

± 67

± 56

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.

^
•vj

TABLE A4.4

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma
glucagon venoarterial differences in untreated, alloxan-diabetic ewes.^*

Hepatic
Treatment

Portal
Vein -

Vein Portal

Hepatic

Artery

Vein

Artery

Vein -

-(pg/ml)
Control

BOHB

Carnitine

68

-26

42

± 15

± 7

± 11

50

-27

23

± 8

± 5

± 4

43

-26

17

± 7

± 5

± 5

1.

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
00

TABLE A4.5

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma free

carnitine venoarterial differences in untreated, alloxan-diabetic ewes,^"

Hepatic
Treatment

Portal

Vein -

Hepatic

Femoral

Vein -

Portal

Vein -

Artery

Vein -

Vein

Artery

Artery^ *

- (MMJControl

BOHB

Carnitine

^•

-0.04

-0.33

-0.37

0.10

± .74

± .56

± .59

± .86

-0.03

0.29

0.26

0.39

± .32

± .30

± .34

± .31

11.09

282.05

± 174.63

± 116.24

_ _ _

^

*

-333.72*

293.14

± 196.47

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

± 166.34

unless column

noted otherwise.

^'

Means ± standard error of means,

n = 12, 3 measurements on 4 ewes.

significantly different from the preceding infusion period, P < .1.
**

Significantly different from the preceding infusion period, P < .05.

"kick

Significantly different from the preceding infusion period, P < .01,

t-*
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TABLE A4,6

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma free
carnitine net flux rates in untreated, alloxan-diabetic ewes.

Portal

Treatment

Drained Visceral

Total

Hepatic

Splanchnic

()Ltmol/min)
Control

BOHB

Carnitine

-1.32

-0.62

-1.94

± 1.23

± 1.23

± 1.56

0.17

0.43

0.60

± .64

± .74

± 1.02

-315.50

489.14

-173.64

± 443.53

± 334.99

± 553.24

1.

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.
(ji
o

TABLE A4.7

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma shortchain acylcarnitine venoarterial differences in untreated, alloxan-diabetic ewes.

Hepatic

Treatment

Portal
Vein -

Vein -

Hepatic

Portal

Vein -

Artery

Vein

Artery

—

Control

BOHB

Carnitine

Femoral

Vein -

Artery''*

^llM^

-0.76

-0.57

-1.33

-1.64

± .69

± .52

± .60

± .97

-0.02

-0.25

-0.27

-1.14

± .58

± .61

± .86

± .79

-108.56

111.10

2.53

-60.29

± 72.18

± 96.09

± 92.18

± 62.14

Means ± standard error of means, n = 18, 3 measurements on 6 ewes, unless column
noted otherwise.

2-

Means ± standard error of means, n = 12, 3 measurements on 4 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

*** Significantly different from the preceding infusion period, P < .01.

U1

TABLE A4.8

Effects of subsequent beta-hydroxybutyrate and L-carnitine infusion on blood plasma acid-

soluble acylcarnitine net flux rates in untreated, alloxan-diabetic ewes.

Portal

Treatment

Drained Visceral

Total

Hepatic

Splanchnic

(/Limol/min)
Control

BOHB

-1.76

-3.82

± 1.33

± 1.59

± 1.88

-0.17

-1.27

-1.44

± 1.56

± 2.34

-2.06

± 1.34

Carnitine

**

-349.44

503.18

153.75

± 138.72

± 443.33

± 379.77

Means ± standard error of means, n = 18, 3 measurements on 6 ewes.

*

Significantly different from the preceding infusion period, P < .1.

**

Significantly different from the preceding infusion period, P < .05.

***

Significantly different from the preceding infusion period, P < .01.

(J1
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ACETOACETATE ANALYSIS

Principle

The acetoacetate analysis is a spectrophotometric
determination based upon a compounds (nicotinamide
adenine dinucleotide, NAD, in this analysis) unique

propertery to absorb a specific quantity of light of

specific wavelenght. Acetoacetate is indirectly
determined from the concentration of NAD following the
chemical reaction:

HOOC-CH2-CO-CH3 + NADH + H"*"
acetoacetate

> HOOC-CH2-CHOH-CH3 + NAD"*"
beta-hydroxybutyrate

Acetoacetate is reduced, in a 1:1 stocheiometry, using
reduced nicotinamide adenine dinucleotide (NADH) in the
presence of the enzyme beta-hydroxybutyrate
dehydrogenase resulting in the formation of betahydroxybutyrate and oxidized nicotinamide adenine

dinucleotide (NAD"*"). The change in absorption between

the reduced and the oxidized forms of nicotinamide
adenine dinucleotide results in the calculation of
acetoacetate.

Treatment of Blood

1)

Mix equal volumes of whole blood and 1 M HCLO4
immediately after sampling.

2)

3)
4)

Centrifuge at 3g for approximately 15 min.

Neutralize excess HCLO4 with KOH so that the final

pH is

between 6.0 and 8.0.

Centrifuge off the potassium perchlorate formed at
approximately 3g for 15 min then pour off the
supernatant.

5)

Samples must be analyzed the day of collection.

Reagents

1)

0.1 M Phosphate Buffer (pH 6.8)

1.36 g KH2PO4

> 100 ml DD H2O

1.74 g K2HPO4

> 100 ml DD H2O
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Mix equal volumes of each solution.

Check pH and add

one or the other to balance pH.

2)

NADH (approx. ImM) (Disodium Salt) (Grade II,
98 % Pure) (Boehringer Mannheim, cat. # 128023)
0.005 g NADH

> 6.0 ml H2O

Make up on day of use.

3)

3-Hydroxybutyrate Dehydrogenase (5.0 mg/ml)
(Grade II) (Boehringer Mannheim, cat. # 127841)

4)

1.5 mM Acetoacetic Acid (ACAC) (Lithium Salt)
(90 to 95 % Pure) (Sigma Chemical Co., cat. # A8509)

0.01620 CH3COCH2COOH g

> 100 ml H2O

Make up on day of use.
Standards

Dilute to the following concentrations for the working
standards:

0.15, 0.09, 0.075, 0.045, and 0.0225 mM.

Use two zero concentration standards as blanks.

The standards must be taken through the entire

procedure as small amounts of perchlorate will affect
enzyme activity. Pipette into conical centrifuge
tubes:

1.0 ml standard and 1.0 ml of 1 M HCLO4.
Neutralize to pH 6.0 to 8.0. (Remember to record the
volume of buffer added to adjust pH !!!).

Centrifuge at 3g for 15 minutes.
Standard dilutions:

2.0 ml of 1.5 mM ACAC plus 18.0 ml H2O

A)

0.15

B)

0.09

C)

0.075

D)

0.045 —>

10.0 ml of B plus 10.0 ml H2O

E)

0.0225 ->

10.0 ml of D plus 10.0 ml H2O

—>
>

12.0 ml of A plus 8.0 ml H2O

—>

4.0 ml of A plus 4.0 ml H2O
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Analysis

Pipette into 12 X 75 mm culture tubes:
0.5 ml buffer

Sample/standard - 1.0 ml for fed sheep and 0.5 ml plus
0.5 ml H2O for fasted sheep.
0.05 ml NADH
Read

at 340 nm.

Add 0.005 ml 3-Hydroxybutyrate dehydrogenase and

incubate at room temperature for approximately 20 min.

Read E2 at 340 nm.
Important

NADH will "react" slowly at room temperature but at
about the same rate in all samples.

The zero

concentration ACAC standards can be used as a control

for this.

Pipette NADH into all of the cuvettes at

known time intervals, i.e., 15 to 60 s.

Then read E^

in all cuvettes at the same timed intervals.

and read E2 at same timed intervals.

Incubate

Calculations

Calculate Ei minus Eo for all standards, samples and
blanks:

Change in E of standard minus change in E of blank
Change in E of sample minus change in E of blank
Plot a standard curve of change in E of standard versus
concentration.

Read the concentration of the samples from the curve.
Multiply by appropriate dilution factors.
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BETA-HYDROXYBUTYRATE ANALYSIS

Principle

The beta-hydroxybutyrate analysis is a
spectrophotometric determination based upon a compounds
(nicotinamide adenine dinucleotide, NAD, in this
analysis) unique property to absorb a specific quantity

of light of specified wavelenght.

Beta-hydroxybutyrate

is indirectly determined from the concentration of NAD
following the chemical reaction:

HOOC-CH2-CHOH-CH2 + NAD

beta-hydroxybutyrate

> COOH-CH2-CO-CH2 + NADH + H"*"
acetoacetate

Beta-hydroxybutyrate is oxidized, in a 1:1
stocheiometry, using oxidized nicotinamide adenine

dinucleotide (NAD"*") in the presence of the enzyme betahydroxybutyrate resulting in the formation of

acetoacetate and reduced nicotinamide adenine

dinucleotide (NADH).

The change in absoption between

the oxidized and the reduced forms of NAD results in

the calculation of beta-hydroxybutyrate.
Treatment of Blood

1)

Mix equal volumes of whole blood and 1 M HCLO4

2)

Centrifuge at 3g for approximately 15 min.

3)

immediately after sampling.

Neutralize excess HCLO4 with KOH so that the final
pH is between 6.0 and 8.0.

4)

Centrifuge off the potassium perchlorate formed at
approximately 3g for 15 min and then pour off the
supernatant.

5)

Samples may be stored at -20° C for at least one
week.

Reagents

1)

0.1 M Tris-HCl Buffer (pH 8.5)

2.42 g Tris
pH

> 50 ml DD H2O

> 8.5 with 1 M HCL

Final volume

> 200 ml
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2)

Hydrazine-Tris Buffer (Burnt bacon buffer)
2.5 ml Hydrazine Hydrate
0.05 g EDTA
12.5 ml 1 M HCl

Volume

> 50 ml with Tris-HCl Buffer

Check pH, should be 8.5
Make up on day of use.

3)

14 mM NAD (Free Acid) (Grade II, 98 % Pure)
(Boehringer Mannheim, cat. # 127990)
0.03 g NAD

> 3.0 ml DD H2O

4)

3-Hydroxybutyrate Dehydrogenase (5 mg/ml)
(Boehringer Mannheim, cat. # 127841)

5)

2.0 mM 3-Hydroxybutyric Acids (Sodium Salt)
(98 % Pure) (Sigma Chemical Co., cat. # H-6501)
0.0656 CH3CHOHCH2COOH g

> 250 ml DD H2O

Standards

Working standards:
2.0, 1.6, 1.2, 0.8 and 0.4 mM

The standards must go through the whole procedure and
are treated as described in the acetoacetate assay.
Standards:

2.0 = 100 %

> 20.0 ml 2.0 mM BOHB plus 0.0 ml H2O

1.6 = 80 %

> 16.0 ml 2.0 mM BOHB plus 4.0 ml H2O

1.2 = 60 %

> 12.0 ml 2.0 mM BOHB plus 8.0 ml H2O

0.8 = 40 %

>

8.0 ml 2.0 mM BOHB plus 12.0 ml H2O
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Analysis

Pipette into culture tubes;
Sample/standard

0.25 ml (fed)

0.1 ml (fasted)

H2O

0.75 ml

0.90 ml

Buffer

0.50 ml

0.50 ml

NAD"*"

0.05 ml

0.05 ml

Read

at 340 nm.

Add 0.005 ml 3-hydroxybutyrate dehydrogenase and

incubate at room temperature for about 45 min.

Read E2 at 340 nm.
Important

NAD and hydrazine form a complex which absorbs at 340
nm.

Therefore, a slow constant increase in absorbance

occurs. This is similar to the acetoacetate assay but
in reverse. So pipette the NAD and enzyme and take the
absorbance readings at timed intervals as described for
the acetoacetate assay.

Calculation

Same as for acetoacetate, except change in E is

calculated from E2 minus E^.
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CARNITINE ASSAY

Supplies and reagents

Equipment:
1.

Scintillation counter

2.

Refrigerated centrifuge

3.

Incubator water bath (shaker)

4.

Automatic pipettes - 'Pipetman' (20,100,200,1000
ml)

5.

Timer and vortex mixer

Supplies:
1.

5-3/4" pasteur pipettes

2.
3.

12 X 75 mm glass test tubes
1.5 ml cap. Eppendorf test tubes

4.

Glass wool

5.

Anion exchange resin, AG 1 x 8, 200-400 mesh, Cl-

6.

Prepare minicolumns of 4.5 cm length in the 5 3/4

7.

Pasteur pipettes. (The fill line is 9 cm from the
tip.)
Prepare phenol red tubes (12 x 75) by placing 1
drop of phenol-red solution in each tube and
evaporating to dryness at R.T.

form BioRad Laboratories

Reagents and Solutions:

la)

0.5 mM Carnitine Standard Solution (stock): LCarnitine HCl (General Biochemicals 3363F Lot 45882).
Dissolve 9.88 mg in cold GDW and bring the total volume
to 100 ml with GDW in a volumetric flask. Dispense 1
ml aliquots into plastic tubes and freeze at -70°C.
Dilute to 0.25 mM for working standard solution.

lb)

22.9 mM L-Palmityl Carnitine Standard (stock): Add 1
ml GDW to the vial containing 10 mg of L-Palmityl
Carnitine (Sigma). Dilute appropriately to make
desired working standard. For example, 10 ill of stock
standards + 990 ill of GDW will give 0.299 mM working
standard.

2)

4N Potassium Hydroxide: KOH pellets from Fisher
Scientific Company. Dissolve 56.11 g in GDW and bring
total volume to 250 ml with GDW.
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3)

0.5 N Potassium Hydroxide:

KOH pellets from Fisher

Scientific Company. Dissolve 28.055 g in GDW and bring
total volume to 1000 ml from GDW. (Caution: very old
stock KOH may not be used.)

4)

0.6 M Perchloric Acid: 70% Perchloric Acid from Fisher
Scientific Company. Add 51.28 ml of 70% Perchloric
Acid to 500 ml of GDW.

5)

Dilute to 1 liter.

O.IM Sodium Tetrathionate (Na2S406•2H2O)(Pfaltz and
Baurer) 0.7656 g of Na2S405-2H20 is dissolved in GDW
and made to volume in a 25 ml volumetric flask.

anhydrous Na2S406 use 0.6756 g in 25 ml of GDW.

For

(Renew

monthly.)

6)

0.1% Phenol Red - Phenol Red (Na-salt) from Sigma
Chemical Company. Dissolve 0.1 g in 100 ml of 100%
ethanol. Add 1 drop of phenol red to 12 x 75 glass
tube and allow to dry.

7)

[l-^'^C] Acetyl Coenzyme A from Amersham, 50 mCi/mmol.

8)

IM Potassium Bicarbonate - from Baker Chemicals.
Dissolve 1.0 g in GDW and dilute to 10 ml. Keep at
room temperature and prepare daily.

9)

O.IM Acetic Anhydride - from Fisher Scientific Company.
Add 0.05 ml of acetic anhydride to 4.95 ml of cold GDW,
mix and use immediately.

10)

O.lmM Acetyl CoA. Coenzyme A from PL Biochemicals.
Dissolve 10 mg of Coenzyme A in 500 nl of cold GDW and

Dissolve 50 ^Ci in 300 ml of cold GDW. Dispense 5 ml
aliquots into plastic vials and freeze at -20°C.

mix.

Add 100 ^1 of IM KHCO3 and mix.

Add 200 ^.1 of

0.1 M acetic anhydride and mix immediately.
volume to 80 ml with cold GDW.

Mix well.

Bring the
Dispense 5

ml volumes and freeze at -20®C.

11)

Carnitine Acetyltransferase (Pigeon Breast Muscle).
Acetyl-CoA:Carnitine-O-acetyltransferase from Sigma

Chemical Company.

Dilute the (NH4)2S04 solution with

GDW to 50 units/ml.
12)

IM MOPS [3-(4 morpholino) propanesulfonic acid] from
Eastman Kodak Chemical Company. Dissolve 20.92 g MOPS
in approximately 80 mg GDW. Adjust pH to 7.4 with 4N
KOH.

Dilute to 100 ml with GDW and store in

refrigerator.
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13)

PCA/MOPS-I: 20.9 g MOPS + 50 ml of 0.6 M PCA, dilute to

14)

PCA/MOPS-II: 20.9 g MOPS + 20 ml of 0.6 M PCA, dilute

15)

O.IM EGTA, pH 7.0: Dissolve 1.902 g EGTA (Sigma) in 30
ml of GDW, neutralize with 4N KOH to pH 7.0. Make to

100 ml with GDW.

Store in refrigerator.

to 100 ml with GDW.

Store in refrigerator.

volume in 50 ml volumetric flask with GDW.

16)
17)

O.lmM [1-^^C]-acetyl CoA solution: Mix 2 volumes of

[1- C] acetyl CoA (#7) and 1 volume of cold 0.1 mM
acetyl CoA (#10). Keep on ice.

Reagent mixture for one assay fraction:
IM MOPS buffer pH 7.4

120 /il

O.IM EGTA pH 7.0

20 /il

O.IM Na2S406

20 /il

O.lmM [1-^^C] acetyl CoA solution

200 /tl

GDW

40 ul

TOTAL

18)

400 /iL

8% Bovine serum albumin (BSA), (Fraction V, F.A. poor

from ICN):

slowly dust 4 g of GSA into about 20 ml GDW

in a beaker with gently stirring.

Dilute to volume

with GDW in a 50 ml volumetric flask.

19a) Scintillation Fluid A for non-aqueous samples.

Add 33

g PPO (2,5-Diphenyl-oxazole) and 1.0 g POPOP (1,4-Bis
(2- (5-Phenyloxazolyl)) Benzene) to 4 liters of toluene
(scintillation grade. Fisher Scientific Co.)

19b) Scintillation Fluid B for aqueous samples.

Add 2 parts

of scintillation fluid A and 1 part of Triton X-100.

Mix without excess agitation or exposure to light.

Instead of 19 a/b, Beckman "Ready-Solve" may be used.

165

Procedure

Preparation of Samples for Carnitine Assay:
A.

Blood Samples:

1.

Draw the blood into a tube containing heparin (15
U/ml blood) or ETDA (2 mg/ml blood). Centrifuge
the blood at 1500 x g for 10 minutes. Remove the
plasma and store frozen at -70°C. Wash the

erythrocytes twice with saline and freeze at 70°C.

2.

Blood cells.

On the day of the assay, lyse the

erythrocytes by thawing, adding an egual volume of
GDW and refreezing. Use triplicate aliquots of
200 111 of hemolysate or 100 jul of plasma for

assay. Determine the plasma protein and
hemolysate hemoglobin.
3.

Blood, Plasma or Serum:

Frozen samples must be

thoroughly vortexed and centrifuged (300 rpm, 10
min) for clear SN and minimum variability. Add
100 111 of plasma to 200 /il of 0.6M PCA contained
in a 12 X 75 mm glass test tube. Vortex. Add 100
jul GDW and centrifuge at 1500 x g for 10 minutes
in a refrigerated centrifuge. Separate SN and use
for carnitine and acid soluble acylcarnitine
(ASAC). Use pellet for determining acid insoluble
acylcarnitine (AIAC). The fraction for the
determination of ASAC and AIAC can be frozen until

analyzed. Nonesterified carnitine should
preferably be assayed without freezing.
B.

Tissue Homoqenization:

1.

Place 1 ml of 0.3 M PCA in glass homogenizers and

keep on ice.
2.

Remove tissue from freezer and keep on ice while
weighing.

3.

Weigh out approximately 100 mg tissue, drop into
homogenizing vessel and homogenize immediately.
Do onlv one sample at a time; do not let tissue
sit in vessel.

4.

Transfer homogenate to thick walled test tube and
rinse vessel twice with 1 ml 0.3M PCA.
exceed final volume of 3 ml.

Do not
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C.

5.

Centrifuge 400 rpm for 10 minutes and transfer SN
to falcon tube and assay for carnitine
immediately.

6.

Drain pellet and freeze until time of assay.

Urine Sample;

Add 20-100 /il of urine to 200 /il of 0.6 M PGA. Vortex.
Add 100 ^il 8% BSA and enough GDW to make a total volume
of 400 /il. Centrifuge at 1500 x g and remove clear SN
for carnitine assay. Urine must be sediment-free
before PCA treatment and thoroughly mixed.
D.

Preparation of Carnitine Standards

0.25 mM CNE 0.23mM P-CNE GDW 8%BSA 0.6M PCA Total Total CNE

(nm) (Ml)

(nm) (Ml) (Ml)

(Ml)

(Ml)

(nm)

0

0.00

0

0.00 100

200

400

0.00

5

1.25

5

1.15

90

2.40

10

2.50

10

2.30

80

4.80

(Ml)

100

15

3.75

15

3.45

70

7.20

20

5.00

20

4.60

60

9.60
14.40

30

7.50

30

6.90

40

40

10.00

40

9.20

20

50

12.50

50

11.50

0

19.20
~~~

~

~ —

24.00

Use 12 X 75 mm glass test tubes.

Mix each tube thoroughly by vortexing.

at 1500 X g for 10 minutes.

Centrifuge in cold

FRACTIONATE OF SAMPLE FOR ASSAY

A.

Step-Wise Procedure for Nonesterifled Carnitine (FREE)
Determination;

1.

Transfer 150 jul of PCA SN into a 12 x 75 mm phenol
red test tube. The contents should be orangeyellow color.

2.

3.

Add 35 /il of IM KHCO3.

Mix should turn golden

yellow after standing. If purple, check acid
dilution and redo sample.
Vortex.

Keep on ice, uncapped for 30 minutes.

not freeze.

Do
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4.

Centrifuge at 1500 x g for 10 minutes in cold and
assay 100

B.

C.

SN as per procedure.

Step-Wise Procedure for Determination of Acid Soluble
Acvlcarnitine (ASAC) or Short-Chain Acvlcarnitine;

1.

Transfer 100 /nl of PGA SN to a 12 x 75 mm phenol
red test tube. The contents should be orangeyellow color.

2.

Add 75 Hi 0.5 N KOH.
red for hydrolysis.

3.

Hydrolyze at 37"C in a shaking incubator water
bath (100 spm) for 30 minutes.

4.

Neutralize with 30 /il PCA/MOPS-II.
turn light orange.

5.

Vortex.

6.

Centrifuge at 1500 x g for 10 minutes.

7.

Assay 100 /il of SN for carnitine as per procedure.

Vortex.

It must be purple

Color should

Keep on ice for 30 minutes.

Step-Wise Procedure for Determination of Acid Insoluble
Acvlcarnitine (AIAC) or Long-Chain Acvlcarnitine:

1.

The pellet should be free of any PCA/SN.

Resuspend pellets in 200 /xl 0.6M PCA, centrifuge
1500 X 6, 10 min. Discard SN. Repeat the
process. Drain off SN thoroughly.
2.

Add one drop of phenol red indicator.

3.

Dissolve pellet in 200 /i of 0.5N KOH. Some
stirring may be required to dislodge the pellet.
Vortex vigorously several minutes to dissolve the
pellet. Contents should be purple red color.

4.

Hydrolyze at 65°C for 60 minutes in a shaking
incubator water bath (100 SPM) or vortex every 15
minutes during incubation.

5.

Neutralize with 100 /il PCA/MOPS-1.
should turn light orange.

6.

Vortex and keep on ice for 30 minutes.

7.

Centrifuge at 1500 x g for 10 minutes in cold.

The contents
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8.
D.

Assay 100 /il of SN for carnitine as per procedure.

Step-Wise Procedure for Determination of Total
Carnitine (TO;

1.

prepare standards in phenol red tubes according to
procedure on page 4, except substitute 0.5N KOH
for the 0.6M PGA,

2.

Prepare samples by adding 100 /il GDW, 100 iJ.1
serum, and 200 /xl 0.5N KOH to phenol red tubes.

3.

Hydrolyze standards and samples at 65°C (100 spm)
for 60 minutes in a shaking incubator water bath.

4.

Add 150 /il of MOPS I to each tube and vortex.

Contents should be light orange indicating
neutralization. Keep on ice for 30 minutes.
5.

Centrifuge at 1500 x g for 10 minutes.

6.

Assay 100 ^ll of SN for carnitine as per procedure.

Assay for Carnitine;

1.

Transfer 100 ixl of appropriate fraction for NEC,
ASAS, AIAC, or TC to a 1.5 ml capacity microtube.

2.

Add 400 jLtl of reagent mixture to each tube.

3.

Add 20 /il of CAT (50-55 U/ml).
mix gently by inversion.

4.

Incubate at 37°C for 30 minutes, 100 spm.

5.

Cap the tube and

At the end of the incubation time, transfer 200 /il
of incubation mixture onto the mini-column.

After

the sample has been absorbed elute with two
portions of 400 /il GDW into a 20 ml scintillation
vial.

6.

Discard columns properly in radioactive solid
waste containers.

7.

Add 10 ml scintillation fluid B (for aqueous
samples). Cap the vial. Mix by swirling, wipe
the outside if soiled. Count the radioactivity in
the scintillation counter.

Or, add 5 ml of Beckman "Ready-Solve" in mini-vials (7
ml cap), mix, wipe, and count.
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GLUCAGON ANALYSIS

Reagents

1)

2)

Glycine (Fisher Scientific Co. #G-46)

Disodium Ethylenediamine Tetraacetate (Na2EDTA) (Fisher

Scientific Co. #5-3111)

3)

Merthiolate (thimerosal) (Sigma Chemical Co. # T5152)

4)

3M NaOH

5)

10 M NaOH

6)

Borosilicate Culture Tubes 12 x 75 (Fisher Scientific
Co. # 14 962 lOB)

7)

Bovine Serum Albumin (BSA) RIA grade (Sigma Chemical
Co. # A 7888)

8)
9)

Benzamidine Hydrochloride (Sigma Chemical Co. #B6506)
Normal Rabbit Serum (NRS) (Miles Laboratories, Inc. #
64-291; 50 ml lyophilized)

10)

Crystalline Beef-Pork Glucagon (Eli Lilly Co, 500 mg)

11)

30 K Rabbit Anti-Glucagon Antibody (1st Ab) 25
(Roger H. Unger, Dept. of Internal Med., University of
Texas, Health Science Center at Dallas, 5323 Harry
nines Blvd., Dallas, TX
75235)

12)

1251-Glucagon (Cambridge Medical Diagnostics Co. #120,

10 /xCi, stable for 10 weeks)

13)

Goat Anti-Rabbit IgG (2nd Ab) (Research Products
International, RPT # 500090, 10 ml)

14)

0.2 N HCl

15)

Polyethylene Glycol (Sigma Chemical Co., P2139)
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Reagent Preparation

1)

0.2 M glycine-merthiolate

Dissolve in 900 ml double distilled (DO) H2O:
15 g glycine
0.1 g thimerosal

Adjust pH to 8.8 with 3 M NaOH

Final volume

> 1000 ml with DD H2O

Store at 2-4°C.

2)

0.05 M EDTA-glycine-merthiolate
Dissolve in 900 ml 0.2 M glycine-merthiolte:
18.6 g Na2EDTA

Adjust pH to 8.8 with 10 M NaOH
Final volume

> 1000 ml with 0.2 M glycine-

merthiolate in a volumetric flask.

3)

Store at 2-4°C.

1% BSA-glycine-merthiolate
Dissolve 1 g BSA in 100 ml 0.2 M glycine-merthiolate.
check pH (should not change)

Use cold buffer in a beaker with a stirring magnet
4)

0.1 M benzamidine-1% BSA - 0.2 M glycine-merthiolate
Prepare 1% BSA-glycine-merthiolate as in # 3 and add

1.566 g benzamidine hydrochloride
Check pH, adjust to 8.8 with 75 /Ltl 3 M NaOH
5)

0.25% normal rabbit serum (NRS)-EDTA-glycinemerthiolate

Dilute 250 111 NRS to 100 ml in 0.05 M EDTA-glycinemerthiolate

Mix immediately before use and store at 2-4°C
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6)

Rabbit anti-glucagon antibody (1st Ab)

The 30 K is shipped lyophilized with a recommended
final culture tube dilution of 1:100,000
To reconstitute Ab with this volume and titer:

Remove stopper (after tapping lightly to dislodge
any Ab on the stopper) and add 5 ml of cold 1%

BSA-glycine-merthiolate. Replace the stopper; mix
by gentle inversion; let solution sit (02-4°C) for
1 hr inverting it every 10-15 min. This gives a
1:200 dilution.

Transfer this solution to a cold 15 ml centrifuge
tube (on ice). Wash the original tube with 5 ml
1% BSA-glycine-merthiolate and add to the original
5 ml to give a 1:400 dilution.
This solution should be frozen and stored in 500

Hl aliquots, using liquid nitrogen and 12 x 75 mm
polypropylene culture tubes
For the assay, use a 1:50 dilution of the 1:400

solution for the working solution. Thaw 1 500 jul
aliquot/ 123 tube assay and dilute to 25 ml using
0.25% NRS-EDTA-glycine-merthiolate

Mix immediately before use and keep at 2-4°C.
7)

Glucagon standard solution

Weigh out 10 mg crystalline glucagon; dissolve in 20 ml
0.02 N HCl to give a solution of 0.5 mg/ml. The
optical density of this solution should be 1.055 § 278
nM (Harris et al., 1979).
If the OD is not 1.055, then correct the dilution to

give an equivalent final concentration assuming that:
0.5 mg/ml

x mg/ml

1.055 OD

actual OD

Dilute 1 ml of the 0.5 mg/ml solution to 100 ml in 1%
BSA-glycine-merthiolate to give a 5 mg//xl solution

Dilute 0.5 ml of this 5 mg/;il solution to 500 ml using
1% BSA-glycine-merthiolate to give a 0.005 mg/iil
solution
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Quick freeze this solution in 2.2 ml aliquots (1.917
ml/standard curve/assay are used)

Standard solution is used in this dilution; thaw
immediately before use and keep at 2-4° C.
8)

Labeled glucagon

Reconstitute using 5.0 ml benzamidine-BSA-glycinemerthiolate and dilute so that ICQ /il contains 8000 cpm
9)

Goat anti-rabbit IgG (2nd Ab)

Thaw the 10 ml received from RPI and quick freeze in 1
ml aliquots

One 1 ml aliquot is diluted to 60 ml using 0.2 M
glycine-merthiolate
Store at 204°C

10)

Normal rabbit serum (NRS)
Should be frozen in a ml aliquots

11)

Polyethylene glycol (PEG)
Make up a 6% solution
Store at 2-4°C

Procedure

Day 1

Add buffer, standard, plasma and 1st Ab, incubate
12 hr

Day 1+12 hr

Day 3

Add labeled glucagon, incubate 48 hr

Add 2nd Ab and PEG, incubate 1 hr, centrifuge,
pour off, count precipitant
Make sure there are adequate quantities of all
reagents before beginning

Mix buffers needed before beginning, usually 12-24
hr beforehand
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Day 1

Thaw:

3 - 500 nl aliquots 1st Ab
3 - 2.1 ml aliquots standard solution
1 - aliquot NRS (at least 250 jul)
3 - 1 ml aliquots of pooled plasma needed
samples (42/assay)

Prepare 100 ml 0.25% NRS-EDTA-glycine-merthiolate and
use to dilute 1st Ab as previously described (1.5 ml
1st Ab

> 75 ml NRS-buffer)

Dispense 1% BSA-glycine-merthiolate, standard solution,
plasma and 1st Ab as needed, vortex tubes and incubate
12 hr at 2-4°C.

Day 1 + 12 hr

Prepare labeled glucagon, add 100 jLtl to all tubes,
vortex, incubate 48 hr at 2-4°C.
Day 3

Prepare 2nd Ab and 6% PEG, mix together the necessary
volume needed as follows:

5 parts cold 6% PEG
2 parts 2nd Ab

Add 1 ml of 2nd Ab/PEG mixture to all but total tubes,

incubate at room temperature for 1 hr, centrifuge at 3
g for 40 min (do not centrifuge or decant total tubes).
Pour off supernatant into a waste bottle
(quickly/gently) and place upside down on Kimwipes in a
foil lined box for 15 min.

Wipe out the top 1/2 of each tube with a Kimwipe on a
wooden applicator stick and count for 1 min.
Dispose of tubes ASAP.
Points to Remember

Keep reagents and assay tubes on ice and cold as much
as practical/possible.
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Keep frozen reagents in a conventional freezer (nonfrost free).

Do not use buffer with BSA stored longer than 4 weeks.
Use scrupulously cleaned glassware.
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ASSAY PROTOCOL

(volumes in fxl)
tube #

BSA-alv-mer

1-3

total

4-6

N.S.

600

7-9

B 0

400

* std/

1st

olasma

Ab

1251

PEG

100

M M »

—

100

1000

200

100

1000

1

200

100

1000

10-12

5

13-15

15

397

3

200

100

1000

16-18

25

395

5

200

100

1000

399

19-21

50

390

10

200

100

1000

22-24

100

380

20

200

100

1000

25-27

200

360

40

200

100

1000

28-30

400

320

80

200

100

1000

31-33

800

240

160

200

100

1000

34-36

1600

80

320

200

100

pool ewe

1000

37-39

100

300

200

100

1000

40-42

unknown

100

300

200

100

1000

122-123

unknown

100

300

200

100

1000

♦standard = 0.005 ng/ml
Unknown concentrations from this standard curve will be

the concentration per 300 /xl plasma, so a dilution
factor of 3.3333 should be used to give the

concentration per ml.
Blood

Collection

Blood should be collected in tubes containing

benzamidine hydrochloride at a final concentration of

0.03 M and Na2EDTA at a final concentration of 1.2
mg/ml.

Prepare tubes by adding 50 jul of the following
benzamidine-EDTA-saline solution per 3 ml of blood
sampled:

dissolve in 1 ml of 0.9% saline:

0.2347 g benzamidine hydrochloride
0.06 g Na2EDTA

APPENDIX 9
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GLUCOSE ANALYSIS

Sigma Chemical Co. # 510 enzymatic colorimetric in
vitro determination for whole blood, plasma or serum is
based upon the following coupled enzymatic reactions:
glucose oxidase

Glucose + 2 H2O + O2

> Gluconic acid + 2 H2O2

peroxidase

H2O2 + o-Dianisidine
(colorless)

> oxidized o-Dianisidine
(brown color)

The intensity of the brown color is measured at 450 nm
and is proportional to the original glucose
concentration.

Reagents

1)

PGO Enzyme, Stock # 510-6 (Preweighed capsules).
Contains glucose oxidase, peroxidase and buffer
salts.

One capsule is diluted with double distilled (DD)
H2O to 100 ml and stored in an amber bottle at 0
to 5° C.
2)

O-Dianisidine Dihydrochloride, Stock # 510-50.

Preweighed vial is diluted with DD H2O to 20 ml
and stored at 0 to 5° C.

1.6 ml of this is added to 100 ml of PGO enzyme
solution.

3)

Glucose Standard Solution, Stock # 535-100.

Consists of a solution of beta-D-glucose, 100

mg/dl in benzoic acid, 0.1 % and stored at 0 to
5

C•

4)

0.3 N Barium Hydroxide Solution, Stock # 14-3.

5)

5.0 % Zinc Sulfate Solution, Stock # 14-4,
ZnS04 * 7 H2O.
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Sample Collection and Preparation

Blood samples should be collected in a container with a
suitable anticoagulant. Immediately after sample is
collected, pipette 0.2 ml blood into test tube

containing 1.8 ml DD H2O, then mix.

To each tube add

1.0 ml barium hydroxide, mix, then add 1.0 ml zinc
sulfate and mix again.
Blank and standard are prepared in a similar manner
except 0.2 ml of DD H2O and 0.2 ml of glucose standard
are used, respectively, in place of the blood.
Tubes are then centrifuged at 3g for 15 min.
at 0 to 5° C.
Analysis

Prepare unknown, blank and standard tubes in duplicate
as follows:

To each tube add 0.25 ml of supernatant from the

respective centrifuged unknown, blank and standard
tubes followed by 2.5 ml of PGO/color solution and mix.
Incubate all tubes at 37° C for 30 min in a waterbath
or at room temperature for 45 min.

Avoid direct exposure to sunlight or bright light.
Following incubation, remove all tubes from the
waterbath.
Read at 450 nm.

Readings should be completed within 30 min.
Calculation
Absorbance Unknown

Blood glucose (mg/dl)

X 100
Absorbance Standard

APPENDIX 10

181

INSULIN ANALYSIS

Principle

The insulin assay is a double antibody radioimmunoassay
which uses guinea pig anti-bovine insulin as the first
antibody (lAb) and goat anti-guinea pig IgG as the
second antibody (2Ab). The procedure is based on the
following assumption:
The assumption is made that
labelled bovine
insulin
and unlabelled (endogenous) insulin (I)
will be bound to the same extent by the first and
second antibodies. Therefore, 50% of the antigenantibody complexes will be the labelled complex and 50%
the unlabelled complex.
+ I + lAb

^^^I-lAb + I-lAb + 2Ab

>

^ i_iAb

> ^2^I-lAb-2Ab + I-lAb-2Ab

These second antigen-antibody complexes, being of high
molecular weight, are centrifuged out of solution and
the ionizing radiation (in the form of gamma rays or
photons) emminating from the labelled antigent-antibody
complex is measured using a gamma counter.

Reagents

1)

Sodium Hypophosphite (NaH2P02 * H2O)
(Fisher Scientific Co., cat. # S-321)

2)

Sodium Chloride (NaCl)
(Fisher Scientific Co., cat. # S-231)

3)

Disodium Ethylenediamine Tetraacetate (EDTA)
(Fisher Scientific Co., cat. # S-311)

4)

Merthiolate (Thimerosal)
(Sigma Chemical Co., cat. # T-5125)

5)

5.0 M Sodium Hydroxide
(Fisher Scientific Co., cat. # S-318)

ICQ g NaOH
6)

> 500 ml DD H2O

Bovine Serum Albumin (BSA)
(Sigma Chemical Co., cat. # A-7888)
(RIA Grade; Fraction V) (50 g)
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7)

Guinea Pig Serum (GPS)

(Research Products International, cat. # 501005)

(15 ml)

8)

Bovine Pancreatic Crystalline Insulin

(Sigma Chemical Co., cat. # 1-5500)

^00 mg)

9)

10)

Guinea Pig Anti-Bovine Insulin (1
antibody)
(Miles Laboratories, Inc., cat. # 65-101-1)
(1.0 ml Lyophilyzed)

^2^1-Insulin

(Amersham Corp.) (5 uCi)

11) Goat Anti-Guinea Pig IgG (2^^^ antibody)

(Research Products International, cat. # 500085)

(10 ml)

12)

Borosilicate Culture Tubes (12 X 75 mm)
(Fisher Scientific Co., cat. # 14-062-10B)

Reagent Preparation

(For 3 assays of 123 tubes each)

1)

Phosphate Buffered Saline (PBS-EDTA)

Dissolve in 800 ml double distilled (DD) H2O:
1.38 g NaH2P02 * H2O
8.77 g NaCL

9.30 g EDTA * 2 H2O Disodium salt
Adjust pH to 7.6 with 5 M NaOH

Add 100 mg thimerosal and bring to 1.0 1 in a
volumetric flask and store at 2 to 4° C.
2)

1.0 % BSA-PBS
Add 1.0 % BSA to cold PBS in a beaker and allow

to dissolve (this takes approximately 2 to 3 h)

while kept at 2 to 4° C.

After BSA is dissolved,

reajust pH to 7.6 using 5.0 M NaOH.

Bring to

desired amount in a volumetric flask and store at

2 to 4° C.
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Note:

A total of 350 ml is needed.

be made on day 1.

assays and dilute labeled insulin.

100 ml to dilute 2^" antibody.
3)

250 ml can

This is enough to set up

On day 3, mix

0.25 % GPS-1.0 % BSA-PBS-EDTA
Add 250 ul GPS to 1.0 % BSA-PBS and bring to 100
ml in a volumetric flask.

4) 1®^ Antibody
Reconstitute lyophilized guinea pig anti-bovine
insulin according to manufacturers instructions.

Use 1.0 ml cold DD H2O and then add 9.0 ml 1.0 %

BSA-PBS- EDTA to give a 1/10 dilution. This
solution is then frozen in 0.15 ml aliquots.
(Use polystyrene tubes).

A 1/8000 dilution is used for the assay. To
obtain this dilution, 0.05 ml of the 1/10
dilution is diluted to 40 ml using 1.0 % BSA-0.25
% GPS-PBS-EDTA.

5)

Insulin Standards
78.43 mg of bovine insulin (Sigma # 15500) is
diluted in 500 ml of 1.0 % BSA-PBS-EDTA (at room
temperature with 1 to 2 h of stirring) to yield a
4 U/ml solution.
Example; if insulin lot contains 25.5 U/mg then
78.43 = 2000 U.

1.0 ml of this 4 U/ml solution is then diluted to
100 ml in 1.0 % BSA-PBS-EDTA to give a 40 mU/ml
solution.

The 40 mU/ml solution is then frozen in 0.5 ml
aliquots using liquid nitrogen and stored at 20° C for future use.
To prepare standard solution, 0.2 ml of the 40
mU/ml solution is diluted to 4.0 ml using 1.0 %
BSA-PBS-EDTA to give a 2.0 mU/ml solution. The

following dilutions of the 2.0 mU/ml solution are
then used to give solutions utilized for a
standard curve:
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2.0 mU/ml solution

Standards

(uU/ml)

BSA-PBS-]

(ml)

(ml)
9.0

200

1.0

120

0.6

9.4

80

0.4

9.6

40

0.2

9.8

20

0.1

9.9

12

0.06

9.94

8

0.04

9.96

4

0.02

9.98

1

0.005

9.995

200 ul of these solutions are then used in each
standard tube.

6)

Labelled Insulin
Labelled insulin is diluted with 1.0 % BSA-PBS-

EDTA to give a solution containing enough ^25j_

insulin so that approximately 10,000 cpm are in a
100 ul sample.

7) 2"^ Antibody
RPI antibody is thawed and diluted 1/80 using 1.0
% BSA-PBS. Currently, RPI antibody is frozen in
1.0 ml aliquots which can be diluted to 80 ml.

This would provide enough 2^^

antibody for 3

assays plus some left over which could be quickly
frozen and thawed prior to reuse.
8)

Guinea Pig Serum (GPS)
Guinea pig serum should be frozen in 400 ul
aliquots.

Procedures

Day 1.

Add plasma/standards, diluent and 1®^ Antibody

Day 2.

Add

Day 3.

Add 2^^ Antibody

Day 5.

Centrifuge, pour of and count precipitate

185

Day 1

Label culture tubes.

Usually, 3 assays are run

containig 123 tubes each.

Currently, the centifuge

can hold 120 tubes (the 3 total tubes are not

centrifuged) and a standard curve is prepared for
each centrifuge load.
Mix 1.0 % BSA with PBS-EDTA before use (usually the
night before) and adjust pH to 7.6.
Thaw an aliquot each of 1
»

antibody, insulin
•

•

•

standard solution and guinea pig serum. Prepare
insulin standard solutions, GPS-BSA-PBS-EDTA (100 ml
is sufficient for 3 assays) and 1
antibody as
previously described.

Dispense BSA-PBS-EDTA and GPS-BSA-PBS-EDTA into
tubes as needed, standard solutions and plasma

samples.

Add 1®^ antibody to all but total and

nonspecific binding tubes.
24 h at 2 to 4° C.

Mix tubes and incubate

Day 2

Prepare labelled insulin and add 100 ul to all

tubes, mix and incubate 24hat2to4°C.
Day 3

Prepare 2^^^ Antibody and add 200 ul to all but total
tubes, mix and incubate 48hat2to4°C.

Day 5

Centrifuge at 3.Og for 30 to 35 min (do not

centrifuge or decant total tubes).

Pour off supernatant into waste bottle (quickly and
gently) and place upside down on Kimwipes in a foil
lined box for at least 15 min.

Wipe out the top half of each tube with a Kimwipe on
a wooden applicator stick and count for 1.0 min.
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Assay Protocol Using 400 ul Samples
(Volumes in ul)
Tube

Plasma/

#

Standard

PBS a GPS

PBS c GPS

1st Ab

1251

2nd Ab

Total
100

1-3
N.S.
500

4-6

100

200

B.O.
7-9

100

400

Std 1
10-12

200

200

Std 4
13-15

Std 8
16-18

Std 12
19-21

Std 20
22-24

Std 40
25-27
Std 80
28-3 0

Std 120
31-33

Std 200
34-36

Pooled
Calf
37-39

400

Pooled
Cow
40-42

Unknowns
43-44
122-123

400

100

100

100

100
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If plasma samples average greater than 20 uU/ml then

the following protocol using 200 ul samples could be
used:

(Volumes in ul)
Tube

Plasma/
Standards

PBS c GPS

1®^ Ab

125-

2"^ Ab

Total
100

1-3
N.S.
4-6

200

400

B.O.
300

7-9

100

Std 1
10-12

200

100

200

100

Std 5
13-15

Std 10
16-18

Std 20
19-21

Std 40
22-24

Std 80
25-27

Std 120
28-30

Std 200
31-33

Pooled
Calf
34-36

Pooled
Cow

37-39

Unknowns
40-41
122-123

100

100

100
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Points to Remember

Keep all reagents and tubes on ice and as cold as
possible.
Calculate volumes of reagents needed before hand and
mix accordingly to avoid waste.

Keep frozen reagents in a non-frost free freezer.
BSA-PBS-EDTA should not be kept more than 4 weeks at 2
to 4° C.

GPS-BSA-PBS-EDTA should not be saved and used again
after more than 2 to 3 d.

Use "scrupulously" cleaned glassware.

"Precision" pipetting is essential.
Pipette solutions directly to the bottom of culture
tubes as much as possible.
Centrifuge using at least 1.5g in a refrigerated

centrifuge at 2 to 4° C.

APPENDIX 11
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NON-ESTERIFIED PATTY ACID ANALYSIS

Principle

NEFA kit from Wako and is based upon the following
reactions:

FFA are activated to CoA ester by aceyl CoA synthetase
(ACS).
ACS

R-COOH + ATP + CoA

>

Acyl-CoA + AMP + PP

Acyl-CoA is oxidized by acyl CoA oxidase (ACOD) to

produce hydrogen peroxide.
ACOD

Acyl-CoA + O2

>

2,3 trans-Enoyl-CoA + H2O2

Hydrogen peroxide is acted on by peroxidase (POD) in

the presence of 3-methyl-N-ethyl-N-beta-hydroxyethylaniline (MEHA) and 4-aminoantipyrine (AAP) to form a

product with a purple color which is measured

colorimetrically at 550 nm.

2 H2O2 + MEHA + AAP

—> Purple Quinone Product + 4 H2O

Reagents

1)

Color reagent "A".

Each vial contains:

Acyl-CoA synthetase
Ascorbate oxidase
CoA
ATP

4 Aminoantipyrine

2)

Diluent for color reagent "A".

Bottle contains

0.05 M Phosphate Buffer, pH 6.9
Magnesium Sulfate
Surfactant

Stabilizers

3)

Color reagent "B".
Acyl-CoA oxidase
Peroxidase
MEHA

Each vial contains:
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4)

Diluent for color reagent "B".

Bottle contains;

Phenoxyethanol
Surfactant

5)

NEFA standard.

Each vial contains aqueous solution

with:

1.0 mM Oleic acid
Surfactant

Stabilizers

Procedure

1)

Preparation of standards:

Dilute the standard provided (1000 ueq/1) with

double distilled (DD) H2O to provide 125, 250 and
500 ueq/liter standards.

Validation tests show

DD H2O is an acceptable diluent.

2)

Preparation of reagents:
Mix color reagent "A" by adding 10 ml of the
specific"A" diluent to each vial. Gently invert
the vial until contents are completely dissolved

and then combine with 13.3 ml of DD H2O.

Mix color reagent "B" by adding 20 ml of the
specific "B" diluent per vial. Gently invert
until contents are dissolved and then combine

with 33.3 ml DD H2O.
Solutions should be stored between 2 to 8° C and
are stable for 5 d.

Do not freeze solutions or

expose them to direct sunlight.
Analvsis

1)

Assay each sample and standard in duplicate.

2)

Add 0.4 ml DD H2O to each tube.

3)

Add 0.1 ml of serum, plasma or standard to each
tube, followed by 0.35 ml of the combined reagent

"A" plus H2O mixture.

Mix and refrigerate for up

to 60 min if necessary.
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4)

Incubate tubes in a waterbath at 37° C for exactly
20 min.

5)

Following incubation, add 0.8 ml of the combined

reagent "B" plus H2O mixture to each tube, mix and

incubate a second time at 37° C for exactly 20 min.

6)

Remove tubes from waterbath, allow to equilabrate
at room temperature for 5 min, then record the OD
at 550 nm using a blank prepared with reagents as
zero.

(Volume in ml)
Tube

Standard

Plasma

Reagent A + H20

Blank

Reagent B + H20

0.35

0.80

0.35

0.80

Std

ueq/1
125

0.025

250
500
1000

Unknown

0.10

Comments

Do not mix reagents and supplies from test kits bearing
different lot numbers.

The assay is sensitive to heparin and plasma samples
using heparin as an anticoagulant are unsuitable.
Samples which are hemolyzed may yield inaccurate
results.

Ascorbic acid interferes with assay so ascorbate
oxidase is automatically included in reagent "A"
mixture in the WAKO kit.

APPENDIX 12
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PARA-AMINOHIPPURIC ACID ANALYSIS

Reagents for Filtrate

1)

Double Distilled (DD) H2O

2)

20% Trichloroacetic Acid (TCA) (CCI3COOH)
(Sigma Chemical Co., cat. # T-6399)

200 g CCI3COOH

> 1.0 liter DD H2O

Method for Filtrate

1)

Pipette 1.0 ml of blood or standard into 15 ml

2)

Pipette 5.0 ml of blood or standard mixture into
second 15 ml centrifuge tube containing 5.0 ml 20%

centrifuge tube containing 5.0 ml DD H2O.

TCA.

3)

Let stand 60 min or overnight (can be left at this
stage if refrigerated).

4)

Filter through Whatman # 4 filter paper into 16 X
150 mm glass culture tubes.

5)

Add boiling chip to each culture tube and place a
marble on top of each tube.

6)
7)

Boil over low heat in water bath for 30 min after
fine bubbles appear in each tube.
Cool at room temperature and remove marbles when
cool.

8)

Standards from 1.5% PAH infusion solution are made

along with this using same method as for blood
filtrate.

Make up a 1:500 dilution for sheep from 1.5%
infusion solution; 1:100 for dog from 0.25%
infusion solution (considered 10:10).
From this dilution make up a standard dilution:
20% = 2:10; 40% = 4:10; 60% = 6:10; 80% = 8:10;
and 100% = 10:10 (stock dilution). Be sure to

run this through the filtrate procedure (do not
have to boil).

Blank mixed with half DD H2O and half TCA (20%).
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Reagents

1)

1.2 N Hydrochloric Acid (HCl) (Fisher Scientific
Co., cat. # A-144-S)
1:10 dilution of 12.4 N HCL close enough

2)

Sodium Nitrite (NaN02) (Sigma Chemical Co., cat. #
S-2252)

100 mg NaN02

> 100 ml H2O

Freshly made up on day of analysis.
3)

Ammonium Sulfamate (NH4OSO2NH2) (Sigma Chemical
Co., cat. # A-8670)

500 mg NH4OSO2NH2

> 100 ml H2O

Made up within a month.
4)

Coupling Reagent N(-1-Naphthyl)Ethylenediamine
(Sigma Chemical Co., cat. # N-5889)

100 mg Ciofl7NHCH2CH2NH2 * 7 H2O —> 100 ml DD H2O
Store in a brown bottle in refrigerator
indefinitely.
Analysis

1)

Pipette 1.0 ml of filtrate into test tube (in
duplicate).

Pipette 1.0 ml of standard into test tube (in
duplicate).

Pipette 1.0 ml of blank into test tube (in
duplicate).
2)

Add 0.2 ml of 1.2 N HCl to all tubes and mix

thoroughly.
Start time clock and add to all tubes:

0.1 ml sodium nitrite and mix thoroughly.
0.1 ml ammonium sulfamate within 3 to 5 min and

mix thoroughly.
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0.1 ml coupling reagent within 3 to 5 min and mix
thoroughly.

Wait 10 min for color development.

Read absorbance on spectrophotometer at 540 nm.
PAH Stock Solution

1)

Para-Aminohippuric Acid (PAH) (NH2C5H4CONHCH2COOH)

2)

Sodium Hydroxide (NaOH) (Fisher Scientific Co.,

(Eastman Kodak Corp., cat. # 5704)
cat. # S-318)

Dissolve each reagent separately in Physiological
Sterile Saline (PSS):

44.8 g NH2C6H4CONHCH2COOH
10.5 g NaOH

Then add NaOH solution to PAH solution and stir.
May have to heat gently to fully dissolve.
Filter through Whatman # 4 filter paper.
Titrate filtrate to pH 7.4 with 1 N HCl or 4 M
NaOH.

Bring final volume to 500 ml.
solution of sodium salt.

Yields a 1.5%
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